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Abstract 
Open angle glaucoma is a chronic disease of the optic nerve, where damage to the visual 
field can result in loss of vision. There is currently no cure for the disease. The four studies 
presented within this thesis aimed to explore aspects of the impact of glaucoma on 
patients’ everyday living and quality of life. The studies were designed to capture aspects 
of the ‘journey’ in glaucoma which may be particularly challenging for the patient; the 
initial stage, where quality of life may be reduced and the accompanying burden of 
ongoing disease monitoring; and the end stage, where significant loss of vision will likely 
cause visual disability and the daunting prospect of undergoing high-stakes ocular 
surgery. In the first study, the relationship between visual field loss (measured using mean 
deviation [MD]) and vison-related quality of life was assessed. Evidence indicated that 
glaucoma has a negative impact on vision-related quality of life, even in the earliest stage 
of the disease. However, the relationship is likely to be non-linear, as certain phases of 
the disease are more likely to have a greater impact than others. Specifically, each 1 
decibel reduction in MD was associated with a decline of 2.3 (out of 100) units on a 
quality of life metric in the early stage of glaucoma (p<0.001), and 4.6 units in advanced 
disease (p=0.009). In the second study, vision-related quality of life was assessed 
amongst a cohort of newly-diagnosed glaucoma patients taking part in a randomised 
glaucoma therapy clinical trial. Responses on patient-reported outcome measures 
(PROMs) were assessed for group differences between treatment arms of the trial. In 
addition, group differences in quality of life between the stable patients and those with 
glaucomatous progression was compared. There were no statistically significant 
differences on PROMs between the two trial arms. Differences between stable and 
progressing glaucoma patients were observed only on PROMs specific to glaucoma 
(Glaucoma Quality of Life-15, p = 0.02; Glaucoma Activity Limitation-9, p = 0.02). In the 
third study, the equivalence of visual field measurement outcomes were assessed 
between patients attending standard glaucoma care services and those attending a novel 
glaucoma service, a virtual clinic. Average MD measurements for 250 patients in the 
virtual clinic were compared with a ‘big data’ repository of patients in the standard 
glaucoma service, which was used to calculate expected MD values. The speed of visual 
field progression between the two groups was also assessed. In the first analysis, 12 
(4.8%; 95% confidence interval 2.5% to 8.2%) virtual clinic patients scored outside the 
90% expected values based on the big data repository. In the second analysis, 1.9% (95% 
confidence interval 0.4% to 5.4%) virtual clinic patients had visual field changes outside 
of the expected 90% limits. In the fourth study, patient and surgeon experiences of 
advanced glaucoma surgery were assessed in a qualitative analysis. Interview transcripts 
underwent thematic analysis where, for the patients, key emerging themes included the 
emotional impact surgery, developing coping mechanisms, and how to improve the 
patient’s surgical journey. For the surgeons, themes included strategies for risk reduction, 
views on training, and the emotional impact of performing surgery on advanced 
glaucoma patients. To conclude, these studies highlight aspects of the patient journey in 
glaucoma where the disease may be most burdensome and troubling for the patient. 
Some practical changes, such as performing monitoring measurements in a virtual clinic, 
or augmented surgical care services for patients with advanced disease may help to ease 
the burden of glaucoma. In addition, the findings from these studies can help to improve 
understanding of the glaucoma journey and serve as an effective resource for learning, 
support, and professional development for patients, relatives, and carers, as well as 
professionals specialising in eye care. 
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Chapter One - Introduction 
The aim of this PhD is to investigate the patient experience of glaucoma and its impact 
on quality of life. Specifically, the purpose was to assess three key patient-centred aspects 
of the disease; measuring, monitoring, and treatment. In order to clarify the aims for this 
work, this chapter gives a summary of relevant background literature. Further details of 
the specific aims of the PhD are outlined at the end of this chapter. 
1.1 Glaucoma definition and epidemiology 
Glaucoma refers to a group of conditions whereby the optic nerve head and retinal 
ganglion cells are progressively damaged, causing loss of vision. Damage caused by 
glaucoma is irreversible, and the disease is the leading cause of blindness in the world 
(King et al., 2013). The number of people living with glaucoma worldwide is estimated to 
be 64 million, and this figure is expected to rise to 76 million by 2020 (Tham et al., 2014). 
Glaucoma affects approximately 3% of the worldwide population aged between 40 and 
80 years, and these estimates rise as age increases (Khawaja et al., 2013). In the United 
Kingdom, life expectancy is increasing (Office for National Statistics, 2011), thus 
glaucoma is set to become a significant burden on the hospital eye services. Indeed, 
treatment can slow glaucomatous vision loss (Heijl et al., 2002), therefore early detection 
is crucial to preserve visual function (Oliver et al., 2002). However, it is predicted that 
many individuals living with glaucoma remain undiagnosed in developed countries, with 
estimates ranging from 30-50% (Shaikh et al., 2014; Chan et al., 2017). 
1.2 Glaucoma risk factors 
Primary open angle glaucoma (POAG) is the most prevalent form of glaucoma, and the 
data collected and utilised in this thesis relate to this variant of the disease. There are a 
number of risk factors in glaucoma, however the only modifiable of these is intraocular 
pressure (IOP) (Crabb, 2016). A person’s IOP is determined by the rate of aqueous (watery 
fluid located in the anterior and posterior chambers of the eye) secretion and the rate of 
outflow via the trabecular meshwork. Aqueous outflow is dependent on the presence of 
resistance at the point of the eye’s outflow channels. In POAG, there is typically an 
insufficient outflow of aqueous and an increase in IOP. At this point it is important to 
note that not all individuals with high levels of IOP have glaucoma, but rather these 
patients are referred to as having ocular hypertension (OHT). Similarly, not all glaucoma 
patients have high IOP, as in the case of normal tension glaucoma. Yet, high levels of IOP 
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have repeatedly been evidenced as risk factor for glaucoma (Gordon et al., 2002; 
Chauhan et al., 2008), and IOP is known to influence disease progression in glaucoma 
(Heijl et al., 2012; Garway-Heath et al., 2015). There are various other risk factors for 
glaucoma including, but not limited to, aging (Leske et al., 2007), family history of the 
disease (Coleman & Miglior, 2008), and ethnicity, where African-Caribbean individuals 
are significantly more likely to develop POAG, with a much earlier onset in this population 
(Racette et al., 2003). 
1.3 Glaucoma pathophysiology 
Glaucoma can cause a reduction in both peripheral and central visual sensitivity. The 
reduction in sensitivity is attributed to the premature death of ganglion cells located in 
the retina (Casson et al., 2012). In order to understand the significance of this damage, it 
is necessary to consider the anatomy of the eye and the process of visual perception. 
Briefly, light enters the eye through the cornea and travels to the retina at the back of 
the eye, where it progresses through layers of cells before reaching the photoreceptors. 
The photoreceptor cells, known as rods and cones, are activated at low and high levels 
of luminance, respectively. In other words, rod cells are responsible for scotopic vision 
and cone cells for photopic vision, and therefore collectively allow the visual system to 
process information at all light intensities. Signals received by the photoreceptor cells are 
communicated toward the axons of the retinal ganglion cells. These axons cover the 
whole area of the retina and are collectively referred to as the retinal nerve fibre layer. 
The retinal ganglion cells allow for the transmission of information from the 
photoreceptors towards the brain via the optic nerve head. However, when the retinal 
ganglion cells become damaged, as with glaucoma, signals cannot effectively be 
transmitted to the optic nerve and brain, resulting in reduced visual sensitivity. 
The result of damaged retinal ganglion cells in glaucoma can lead to patches of 
poor vision where the brain receives no information. The patches are referred to as 
scotomas. Scotomas are regions of vision loss, or areas of an individual’s visual field which 
is not apparent, or which are ‘missing’. Individuals with glaucoma do not perceive their 
vision loss as a black tunnel or areas of perceptive blackout; rather, these areas are more 
likely to be described as blurry or missing regions, see Figure 1.1 (Crabb et al., 2013). 
Hence patients are typically unaware of glaucomatous vision loss in the early stages of 
the disease. Yet, many studies note that glaucoma patients report greater difficulty with 
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visually demanding tasks as the severity of their glaucoma increases (Ramulu, 2009; 
Jampel et al., 2002; van Gestel et al., 2010; McKean-Cowdin et al., 2008). These findings 
suggest that as glaucoma progresses and becomes more advanced, vision loss may 
become more perceptible to the patient. However, as the visual fields of both eyes 
overlap, normal vision in one eye may compensate for a defect in the affected eye, 
resulting in the visual loss being unnoticeable for the patient (Safran & Landis, 1999). 
This phenomenon, referred to as ‘filling-in’, can explain why glaucomatous visual field 
loss may only begin to affect patients’ activities when the disease is quite advanced and 
vision loss is bilateral (Crossland & Rubin, 2007). 
Figure 1.1: Images used to portray commonly used simulations of the point-of-view of an individual with 
glaucomatous vision loss. Percentages given [%] refer to the proportion of respondents (N=50) stating the 
depiction is representative of their vision. A: Black tunnel [0%], B: blurred tunnel [4%], C: black patches [0%], 
D: blurred patches [54%], E: missing parts [16%], and F: no difference [26%]. (Crabb et al., 2013). 
15 
 
1.4 Detecting and monitoring glaucoma 
The onset of glaucoma is insidious as the patient is typically unaware they have the 
disease in its early stages. Often, glaucoma is detected through opportunistic case 
finding during patients’ routine examination at their local optometrist (Lawrenson, 2013), 
where patients are then typically referred into the hospital eye service for evaluation 
(Bowling et al., 2005). Diagnostic evaluation consists of examination of the anterior 
chamber angle, the reference standard for which is gonioscopy, measurement of IOP via 
tonometry, imaging of the optic discs, and visual field testing (Tuulonen et al., 2003). 
Once diagnosed, glaucoma requires lifelong monitoring, and this is typically carried out 
in secondary care. IOP is monitored and any changes to visual function are assessed 
through visual field testing. Structural changes to the eye are assessed via photography 
and scanning technologies, such as fundus photography and optical coherence 
tomography (OCT). The decision regarding how often patients’ glaucoma should be 
evaluated typically depend on the severity of the disease and the patient’s age. Stable 
glaucoma (usually defined as unchanged visual field and IOP within target range) is 
considered low clinic risk and is typically reassessed every twelve to eighteen months, 
while advanced or progressing glaucoma is monitored more closely, with clinic visits 
scheduled approximately every one to six months until stable, depending on certainty of 
progression and control of IOP (The Royal College of Ophthalmologists, 2016; NICE, 
2017). Yet, determining glaucomatous progression is challenging due to measurement 
variability (Henson et al., 2000; Sultan et al., 2009), thus several clinic visits are usually 
required in order to assess disease progression. 
1.4.1 Gonioscopy 
Gonioscopy is used to assess the structure of the angle of the anterior chamber. The 
configuration of the angle is used to determine the type of glaucoma, where a wide angle 
is indicative of POAG. Conversely, a narrow angle is associated with angle closure 
glaucoma. In POAG, gonioscopy is used to monitor the width of the angle and a 
numerical grade can be assigned. 
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1.4.2 Tonometry 
Tonometry is the objective assessment of IOP. Whilst elevated IOP is not always 
synonymous with glaucoma, it remains the only modifiable risk factor. As such, 
tonometry is pivotal in the monitoring of glaucomatous progression. Tonometry 
assessment measures the amount of force required in order to compress a small area of 
the cornea and reports the pressure reading in terms of millimetres of mercury (mmHg). 
The reference standard for tonometry is Goldmann applanation tonometry (GAT) 
(Wessels & Oh, 1990). GAT is an example of contact tonometry whereby a small probe is 
used to acquire an IOP reading. Other forms of tonometry include non-contact and 
rebound methods, both of which do not require anaesthesia, the former relying on a jet 
of air, and the latter using a bouncing probe to measure IOP. Central corneal thickness 
has the potential to bias tonometry measurements which can result in overestimations 
or underestimations of IOP levels (Copt et al., 1999). As such, it is not recommended to 
rely solely on tonometry when assessing disease progression in glaucoma. 
1.4.3 Fundus photography 
Assessment of the fundus (optic nerve head; retina; and blood vessels) is essential when 
monitoring the health of the eye. Changes in the appearance of the optic nerve can often 
occur prior to any loss of vision observed in glaucoma. As such, assessment of the optic 
nerve head is valuable for diagnosing glaucoma, particularly in the early stages of the 
disease (Weinreb & Khaw, 2004). The optic nerve head is visualised through 
opthalmoscopic examination (direct or slit-lamp biomicroscopy methods), or digital 
fundus photography. During examination, the assessor will estimate the amount of nerve 
tissue that is present at the optic nerve head, such as by calculating the cup-to-disc ratio 
(Quigley et al., 1992), where the cup is located in the centre of the disc shape of the optic 
nerve head. A cup-to-disc ratio of 0.3 (the cup occupies a third of the height of the entire 
disc) is generally considered healthy, and an increased cup-to-disc ratio may indicate 
glaucomatous damage. The usefulness of fundus assessment is dependent on observer 
skills, where there is often high inter-observer and intra-observer variation (Gaasterland 
et al., 2001). 
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1.4.4 Optical coherence tomography 
Optical Coherence Tomography (OCT) is a non-invasive imaging system which provides 
high resolution cross-sectional images of different parts of the eye, including the retina 
and optic nerve. OCT can provide important information regarding the presence of 
glaucoma by examining the retinal nerve fibre layer (RNFL). The RNFL will be relatively 
thick in a healthy eye, and the detection of ‘thinning’ may be indicative of glaucoma 
(Quigley, 2011). Yet, a valid determination of changing RNFL requires an accurate 
baseline measurement against which future measurements can be compared.   This can 
sometimes be challenging as factors including older age, poor best-corrected VA, greater 
degree of myopia, and presence of cataracts have been associated with reduced signal 
strength in OCT which may impact the validity of the image (Lee et al., 2018). 
1.4.5 Visual fields 
The visual field test is used to detect defects in the central and peripheral areas of vision, 
thus, is a vital component to glaucoma diagnosis and monitoring. The visual field is 
defined as the area where light reaches the retina and stimulates the photoreceptors, 
which transmit electrical signals to the brain via the retinal ganglion cells (Werner 1991; 
Henson, 2000). The functionality of the visual field is assessed using perimetry. The 
Humphrey Field Analyser (HFA; Carl Zeiss Meditec, Dublin, CA) is considered the gold 
standard for performing perimetry (Beck et al., 1985). When using the HFA, the individual 
is required to place their head onto the chin support facing into the machine. A small 
light stimuli will then be presented at various locations which correspond to different 
locations on the retina. The individual is asked to fixate at the central point and respond 
each time they see the light stimuli by pressing a button. The test is usually performed 
monocularly, where one eye will be occluded. There are a number of different testing 
patterns, such as the 10-2 and 30-2, but the 24-2 is usually the most common. Put simply, 
the ‘24’ refers to the fact this test is measuring the visual field extending out to 24° from 
the central fixation point in all four directions (thus, the central 48° of the visual field). 
The second number, the ‘2’, indicates that the test is the second variation of the testing 
pattern (now routinely used over the previous patterns, i.e. 24-1). Defects within the visual 
field are identified if light sensitivity at a specific location is below the average sensitivity 
that would be recorded by a person of a similar age with healthy vision, known as age-
matched controls. Information generated in the visual field test is summarised into a 
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number of ‘global indices’ which are reported on the output created by the machine 
(Figure 1.2). One such output is the mean deviation (MD), which indicates how much, on 
average, the individual’s visual field sensitivity deviates from the age-matched normal, 
and is reported in decibels (dB). In research, it is common to use the MD as a metric for 
assessing how glaucomatous the individual’s visual field appears to be. Lower scores are 
indicative of greater damage to the visual field. For example, one crude method is to use 
dB bins of: better than -6dB, between -6dB and -12dB, and worse than -12dB for early, 
moderate, and advanced glaucoma, respectively. These MD groupings will often be 
corroborated by other clinical measurements (Kotecha et al., 2015a). This thesis will 
primarily use visual field MD as a metric for assessing glaucoma severity. Another metric 
provided by HFA is the pattern standard deviation (PSD), which gives information about 
localised vision loss. This is useful as the presence of cataracts can result in misleading 
visual field outputs (e.g. cataracts cause the eye’s lens to become opaque leading to 
excessive light scatter which the PSD metric can account for by correcting for overall 
depression in light sensitivity (King et al., 2013)). The HFA output also provides displays 
which offer valuable information about the functionality of the visual field, such as the 
numerical display giving the threshold for all points of the visual field. These are referred 
to as the point-wise visual field data and can provide sensitive estimates of visual function 
(Bryan et al., 2013). The visual field greyscale image offers a simpler means of interpreting 
the test results, whereby decreasing sensitivity is represented by darker tones. It is 
important when assessing visual field results to take into account the reliability indices 
as these will reflect the extent to which the patient’s results are reliable and therefore 
should be analysed first. Fixation losses, false positives, and false negatives are used to 
assess reliability, and unreliable measurements may require repeat testing. 
The visual field test can be time-consuming and challenging for the patient to 
complete (Glen et al., 2014). This can be problematic as fatigue and learning effects are 
likely to impact the reliability of the measurements (Heijl & Bengtsson, 1996). Fatigue 
may artifactually decrease visual field sensitivity estimates, whereas learning effects may 
result in improved sensitivity between examinations. The latter can be explained by the 
patient being unfamiliar with the visual field testing method in their first attempt at 
performing perimetry. This is often remedied by excluding the first recorded visual field 
from analyses (Artes et al., 2005). 
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Figure 1.2: An anonymised HFA output portraying a visual field produced by a right eye. The measurement 
is indicative of a superior arcuate defect. Fixation losses, false positives and false negatives are indicated in 
the top left. Outlined red are the reliability indices, outlined blue are the numerical and greyscale displays, 
outlined green are the MD and PSD global indices. 
 
1.4.6 The burden of monitoring glaucoma 
Glaucoma patients require lifelong monitoring and this can consume patients’ time and 
other resources. Patients can expect their hospital visits to take up to three hours, not 
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including transport time (Kotecha et al., 2015a). The duration of appointments can impact 
glaucoma patients financially, whereby costs of travel to the hospital, as well as loss of 
income due to absenteeism from work can negatively affect quality of life (Kong et al., 
2014). In addition, patients are often accompanied on their hospital visits by a family 
member or care provider (Sharma et al., 2010), which may result in the patient having 
feelings of being a burden, potentially causing further repercussions for quality of life. A 
recent report from the Royal National Institute of the Blind (RNIB) stated that a primary 
concern for glaucoma patients was the long delays experienced in the hospital eye 
services, citing a fear that such delays can result in disease progression and loss of vision 
(RNIB, 2013). Novel services aimed to combat long clinic visits and waiting times have 
been implemented, such as virtual glaucoma monitoring, and are described further in 
the following section. 
1.4.7 Virtual glaucoma clinics 
One resolution for long hospital waiting periods is the implementation of virtual 
glaucoma clinics in the hospital eye service. Virtual clinics allow for rapid testing whereby 
nurses or ophthalmic technicians collect clinical data from the patients in a streamlined 
fashion, often from a sole clinic room, for a consultant ophthalmologist or a delegated 
glaucoma reviewer to review at a later time (Figure 1.3). The patients are then informed 
of their results approximately one week later via email or telephone, as preferred. 
Figure 1.3: Layout of a virtual glaucoma monitoring system where patients perform clinical testing at a 
number of relevant stations. Image taken from Digital Health and Care Congress, 2017, The King’s Fund.  
(https://www.kingsfund.org.uk/sites/default/files/media/Aachal_Kotecha.pdf). 
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Patients who are monitored in a virtual glaucoma clinic are those who are deemed 
suitable for the service at the discretion of their referring consultant. Standards for virtual 
clinics in glaucoma care in the National Health Service (NHS) hospital eye service suggest 
this method of monitoring may be suitable for patients with OHT, suspected open angle 
glaucoma, or early/moderate primary open angle glaucoma in the worse eye (The Royal 
College of Ophthalmologists, 2016). 
The virtual glaucoma clinic service has been found to improve in-patient capacity 
and streamline referral rates (Kotecha et al., 2015a). A virtual service has the potential to 
improve aspects of quality of life in glaucoma patients, too. For example, the average 
visit to the virtual clinic is less than one hour, compared to three hours in standard care 
(Kotecha et al., 2015b). As a result, the carer burden will likely be lower for virtual clinic 
patients compared to patients in the standard service, as appointments would be 
significantly shorter. In addition, transportation and parking fees have been ranked as 
high cost outgoings for patients in hospital-based glaucoma care (Sharma et al., 2010). 
Hospital parking fees for patients have increased (Rye & Ison, 2005), and shorter visits 
will benefit regular hospital attendees financially. Evidence suggests that patients are 
generally accepting of having their glaucoma monitored in a virtual service, as long as 
they are kept well informed and believe that the staff working in the clinic are suitably 
competent (Kotecha et al., 2015b). Yet, it is important to consider that a virtual service 
may not be appropriate for all patients, including those who fit the virtual clinic eligibility 
criteria. Patients may report feelings of discomfort about the fact they do not come into 
direct contact with a doctor while at a virtual clinic appointment, which may subsequently 
increase patient anxiety (Kotecha et al., 2015b). Furthermore, while virtual clinics are 
designed to support a more streamlined service, evidence suggests that this method of 
monitoring is less cost-effective than standard services due to greater clinic re-
attendances often required (Jones et al., 2018). 
 It is important to consider whether the virtual glaucoma service is a viable means 
of monitoring patients, and this is investigated further in this thesis (see Chapter 4). 
Although no quality of life metrics were used in this study, the idea was to explore 
whether patients whose glaucoma is no longer stable, and so requiring closer 
observation, are effectively identified by clinic staff. The results of the study can have 
significant implications for the way in which glaucoma patients are monitored in the 
hospital eye service, and consequently affecting patient quality of life. 
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1.5 Treatment of glaucoma  
Management of IOP can slow glaucomatous retinal ganglion cell damage. A number of 
well-designed clinical trials have demonstrated the vision-preserving benefit of reducing 
IOP in patients with glaucoma and ocular hypertension (Kass et al., 2002; Heijl et al., 2002; 
Garway-Heath et al., 2015). There are several methods which may be employed to reduce 
patients’ IOP, the first line treatment typically being eye drops. The decision to begin 
topical treatment should not be taken lightly. In most cases, initiation of treatment 
commits the patient to lifelong therapy, or until the treatment becomes ineffective. In 
addition, treatment can often lead to side effects, such as ocular surface discomfort, 
which may significantly affect the day-to-day life of the patient (Schweitzer et al., 2001; 
Nordmann et al., 2003; Skalicky et al., 2012). The decision of whether or not to initiate 
treatment is often based on how aggressive the disease is, i.e. is glaucomatous damage 
progressing rapidly or slowly for the patient. In cases of very slowly progressive disease, 
patients may not be prescribed eye drops immediately so that they are not unnecessarily 
exposed to the side effects, costs, and inconvenience that are associated with glaucoma 
treatment. On the other hand, treatment should not be delayed for patients who are at 
high risk of glaucomatous progression. The Ocular Hypertension Treatment Study (Kass 
et al., 2002) evidenced that topical medications can delay the onset of glaucoma in 
patients with elevated IOP. However, the authors note these results should not imply that 
all patients with elevated IOP should be treated with hypotensive medication. Rather, the 
decision to recommend treatment should consider many factors, such as the burden of 
long term treatment, the individual’s likelihood of being helped by treatment, the 
individual’s health status, and the fact that the overall incidence of patients with elevated 
IOP developing glaucoma is low (Gordon et al., 2002). 
1.5.1 Medical Therapy 
Most glaucoma medications are administered topically and in the form of eye drops. 
Glaucoma eye drops are hypotensive agents which aim to reduce IOP. As a general rule, 
one medication will be prescribed with the aim to achieve a target IOP which is set by 
the patient’s clinician.  
 Prostaglandin Analogue: The most widely used anti-glaucoma medications are 
prostaglandin analogues, which aim to increase aqueous outflow away from the eye 
(McKee et al., 2005). Common prostaglandin analogues include Latanoprost, Travoprost, 
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and Bimatoprost. Prostaglandin analogues are the preferred choice for most patients due 
to the fact they need to be administered only once per day (Li et al., 2006). However, 
there are a number of ocular side effects associated with the use of these medications, 
including irritation, foreign body sensation, increased pigmentation, and longer 
eyelashes. Systemic side effects of prostaglandin analogues can include occasional 
headache and upper respiratory tract symptoms, such as coughing and sneezing.  
Beta-Adrenergic Agonists: Beta-blockers may also be prescribed as an anti-
glaucoma medication. The most frequently used Beta-blocker in glaucoma care is Timolol 
which aims to lower IOP by reducing aqueous secretion. Beta-blockers are often more 
effective when prescribed as an adjunct to, or in combination with prostaglandin 
analogues. Use of Beta-blockers has been shown to correlate with exacerbated 
breathlessness which can be problematic for individuals with asthma or chronic 
obstructive pulmonary disease (Diggory et al., 1995). In addition, prolonged usage of 
Beta-blockers has been associated with mood alterations, decreased libido, and 
impotence (Shore et al., 1987). Moreover, these side effects are likely more common than 
acknowledged as it is not typical for ophthalmologists to ask patients about such 
systemic side effects, and patients may not associate them with their medication 
(Stamper, 2002). 
Carbonic Anhydrase Inhibitors: These topical medications, such as Dorzolamide 
decrease IOP by reducing the formulation of aqueous. Although slightly less effective 
than Beta-blockers, Carbonic Anhydrase Inhibitors (CAI) are often preferred due to being 
well tolerated by patients (Balfour & Wilde, 1997). When used on their own, CAIs may 
require three-times daily dosing (Stamper, 2002) which can result in poor adherence to 
medication (Gurwitz et al., 1993). Serious side effects associated with CAIs are rare, but 
episodes of hypotony and choroidal detachment have been documented (Fineman et al., 
1996). 
Alpha-Adrenergic Agonists: Such agents as Brimonidine are potent IOP lowering 
medications with similar efficacy to Timolol (Katz, 1999). Alpha Agonists attempt to lower 
IOP by both increasing aqueous outflow and decreasing its formation. The medication is 
usually most effective at twice-daily dosing, and in some cases, three-times-per-day. 
Drowsiness, dry mouth, headache, and dizziness are uncommon but potentially 
24 
 
significant side effects associated with Brimonidine (Javitt & Goldberg, 2000; Stamper, 
2002). 
 Non-adherence to topical medication is a concern in glaucoma treatment. There 
are a number of factors which can lead to non-adherence, including high frequency of 
treatment administration (2+ administrations per day) and the presence of multiple other 
medications in the patient’s therapy regimen (Gurwitz et al., 1993). In addition, glaucoma 
patients often do not perceive any vision loss, especially in the early stages of the disease, 
and so do not consider medication adherence to be necessary, or the patient does not 
fully understand their diagnosis of glaucoma, or how to correctly use their medication 
(Shaw, 2005). There are a number of strategies that can be employed to improve 
medication adherence, such as introducing a simpler treatment regimen, combination 
treatments if more than one drug is required, effective communication and 
encouragement regarding the importance of regular treatment, and regular review and 
reassurance to the patient. Educating patients about their disease can be an inexpensive 
means of maintaining high medication adherence (Cate et al., 2014). Moreover, those 
who are most at risk of glaucoma, i.e. the elderly population, can also suffer with 
problems regarding dexterity, such as arthritis, which can make successful administration 
of drops particularly challenging. 
1.5.2 Laser Therapy 
There are a number of different laser treatments available that aim to lower IOP. The 
selective laser trabeculoplasty (SLT) is a routinely used treatment in which the laser is 
directed to the trabecular meshwork (Latina & Tumbocon, 2002). The SLT is considered 
a safer option over the previous gold standard, Argon laser trabeculoplasty (ALT), mainly 
due to the fact SLT can specifically target cells that require treatment within the trabecular 
meshwork (melanin pigment is targeted while non-pigmented cells and structures are 
unscathed). SLT can enhance trabecular outflow (Kagan et al., 2014; Leahy & White, 2015) 
which in turn, reduces IOP. The procedure can provide sustained IOP reduction for a 
number of years. As a result, there is less of a dependence on topical medications and 
this may preserve the integrity of the ocular surface. Research surrounding the use of SLT 
as opposed to Latanoprost as a first-line treatment for glaucoma suggests medical 
therapy may have a greater success rate than laser therapy (Nagar et al., 2005). Yet, SLT 
has the benefit of usually being a one-time intervention which does not require patient 
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adherence as with medical therapy. Laser therapy is relatively quick to perform and does 
not require general anaesthetic. The procedure is usually then implemented if topical 
medications are ineffective, or when patients are unable to adhere or tolerate the side 
effects of ocular drops. Laser therapy has been evidenced as an effective means of 
lowering IOP when first line medications have been ineffective (Juzych et al., 2004; Heijl 
et al. 2002). In addition to ALT and SLT, aggressive laser therapies may be used in cases 
where IOP remains uncontrollable. Cyclodestructive procedures, such as Cyclodiode laser 
ablation, lower IOP through the part-destruction of the ciliary body to reduce aqueous 
secretion. Cyclodiode laser therapy can be successful in providing pain relief in advanced 
glaucomatous eyes with very high IOP (Martin & Broadway, 2001). 
1.5.3 Surgery 
Surgical intervention is often the final line of treatment for glaucoma. That is, surgery is 
usually opted for after topical and laser therapies have not achieved the desired results. 
For patients with severe glaucomatous damage, or those who are poorly adherent to 
medications, surgery may be offered as a first line treatment. Trabeculectomy is the most 
commonly performed incisional glaucoma surgery to lower IOP (Figure 1.4). The surgery 
consists of a small incision in the trabecular meshwork and adjacent tissue to provide a 
drainage route for the aqueous fluid to leave the eye. Scarring during the healing process 
can cause this route to close resulting in a re-increase in IOP. Mitomycin C (MMC) is 
applied during the surgical procedure which helps to prevent scarring by inhibiting the 
growth of cells which are responsible for the production of scar tissue (Khaw et al., 1992). 
Injections of anti-scarring agents, such as antivascular endothelial growth factor (Anti-
VEGF), can be applied to the surgical site during post-operative care to increase the 
success rate of surgery (Zhongqui et al., 2009). However, these injections can also 
increase the rate of complications and the long-term effects of usage have yet to be 
realised (Slabaugh & Salim, 2017). Alternative forms of surgical intervention are available, 
such as artificial tubular drainage implants, which attempt to regulate aqueous outflow 
to reduce IOP. This intervention is considered particularly invasive and expensive and, 
thus, are usually prescribed when an aggressive approach to treatment is required, or 
when previous interventions have been unsuccessful (NICE, 2009). 
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Figure 1.4: An image of a flap valve being created to allow aqueous outflow in a trabeculectomy procedure. 
Image taken from International Ophthalmology Portal (http://iop.vision). 
 
Researchers have recognised the unique impact ophthalmic surgery can have on 
patients’ psychological wellbeing. However, such studies are mainly orientated towards 
the emotional impact of cataract surgery on patients with binocular vision (Nijkamp et 
al., 2004; Marback et al., 2007). In a study comparing patients with binocular or monocular 
vision undergoing cataract surgery, individuals who had only one eye reported greater 
fear of surgery, citing blindness, worsened vision, and surgical complications as their 
primary concerns (Marback et al., 2012). Furthermore, fear of blindness following 
trabeculectomy has been reported in patients with advanced bilateral glaucoma (Cross 
et al., 2009), and even in patients with early glaucoma and fairly good binocular vision 
(Janz et al., 2001). Yet, there appear to be no studies to date which specifically focus on 
the experiences of glaucoma patients undergoing surgery on their one only-seeing eye 
(Figure 1.5). This advanced glaucoma ‘only-eye’ population represents a unique group of 
patients in the hospital eye service who have experienced unprecedented challenges in 
their treatment journey, such as loss of vision monocularly, usually multiple failed 
interventions, and numerous surgical procedures. These patients can provide insight into 
experiences of late-stage glaucoma and surgical intervention which can be used as an 
important resource for professional development and patient education. This idea is 
explored further in a qualitative study described in Chapter 5 of this thesis. 
 
27 
 
Figure 1.5: A painting from the educational project entitled ‘Prize your Eyes’ whereby schoolchildren were 
asked to reflect on the causes and impact of major eye trauma – one of which being an illustration of  
monocular or ‘only-eyed’ vision. Image courtesy of Professor Peter Shah (personal communication). 
 
1.6 Vision-related quality of life  
Quality of life is a broad and multifaceted concept. It can be described as the sense of 
personal satisfaction with the conditions in which one lives (Elliott et al., 2007; Felce & 
Perry, 1995). It may also be defined as the difference between a person’s expectations 
and their present experiences (Aberg et al., 2005). A number of factors can influence 
quality of life, including mental health, physical ability, social function, and independence 
(Carr et al., 2001). Indeed the components that make up a good quality of life will be 
unique for each individual, yet, vision is consistently a key determinant (Altangerel et al., 
2004; Cahill et al., 2005). The concept of vision-related quality of life can be described as 
the extent to which an individual is satisfied with their visual ability and how their vision 
impacts their day-to-day life (Asaoka et al., 2011). 
1.6.1 Assessment of vision-related quality of life 
Vision-related quality of life can be assessed using qualitative or quantitative methods. 
In clinical practice, vision-related quality of life is often assessed qualitatively whereby 
the patient is asked about their visual function, general wellbeing, and satisfaction with 
their care. This form of history taking is typically performed when the patient attends 
clinic appointments. Based on the patient’s responses, an assessment will be made 
whether to continue or adjust the patients’ treatment plan. When vision-related quality 
of life is measured in clinical studies, research protocols usually favour quantitative 
assessments, such as standardised, self-reported questionnaires, typically referred to as 
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patient-reported outcome measures (PROMs). Unlike qualitative history taking, PROMs 
provide a more robust method to quantify vision-related quality of life.  
1.6.2 Patient reported outcome measures (PROMs) 
The use of PROMs in research is well established and can provide valuable evidence 
regarding patients’ quality of life and can contribute to the patient care journey in a 
number of ways, including: improving communication between the physician and 
patient; identifying and prioritizing problems for treatment; screening for unmet needs 
that warrant referral; identifying patient preferences among outcome goals with 
anticipated benefits to adherence to treatment; monitoring changes that may not be 
evident via clinical testing; training new staff in clinical skills; and informing clinical audit 
and clinical governance (Higginson & Carr, 2003). Much of the usage of PROMs has been 
within observational studies and clinical trials in a number of fields of medicine, including 
cardiology (Cleland et al., 2009), oncology (Luckett et al., 2009), and osteology (Hamilton 
et al., 2013). Attention is now being placed on involving the patient throughout clinical 
innovation, and PROM data are increasingly being used to provide evidence for drug and 
device approval (Food and Drug Administration, 2006). Furthermore, there is growing 
attention directed towards the optimisation and personalisation of PROMs through the 
use of item banking and computerised adaptive testing techniques. Qualitative research 
in the area of diabetic eye disease has been used to develop a diabetic retinopathy-
specific quality of life item bank (Fenwick et al., 2010). An item bank is a set of items used 
to measure a specific domain that have been calibrated for difficulty on the same scale. 
Items are selected from the item bank by a computer algorithm according to the 
perceived ability level of each participant and their responses to previous questions until 
a predefined stopping criterion (e.g. measurement precision or number of items) is 
reached (Lamoureux & Fenwick, 2019). Lamoureux et al. (2019) describes this method as, 
if a patient has no difficulty with ‘cooking a meal’, the next selected item would relate to 
a task which is assumed to be a more difficult task such as ‘reading the newspaper’. 
Conversely, if ‘negotiating stairs’ is a challenge, a presumed ‘easier’ task like ‘watching 
TV’ will be presented. Item banking and adaptive testing may provide a more 
sophisticated and user-friendly approach to assessment of patient-reported outcomes 
than traditional paper-pencil PROMs as they may be flexible and adaptable, potentially 
allowing for more precise and valid measurements of the desired domain, with the added 
benefit of fewer items required for the patient to complete (Gershon, 2005). Yet, it can 
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be argued that the assumption in computer adaptive testing that certain tasks are 
presumed to be easier and therefore not relevant to be questioned is directly in contrast 
of the ‘user-friendly’ and patient-centred approach that the model seeks to achieve. 
Indeed, the use of computer adaptive testing method in quality of life assessment in 
ophthalmology remains in its infancy, and a tool specifically designed to assess glaucoma 
remains under construction (Lamoureux, 2018). 
PROMs can be useful to systematically measure changes in visual functional 
ability over time, as well as monitoring changes in patient satisfaction. Patient-reported 
outcome measures can be broad, assessing multiple aspects of general health and quality 
of life, or highly focused on a particular attribute. Most PROMs are based on self-
evaluation of function and feature several items relating to a specific functional ability. 
Typically, respondents will mark their answers on a Likert scale (e.g. scored 0 to 5). An 
example of a PROM structure and response scale is shown in Figure 1.6. PROMs can be 
broadly divided into those assessing general health, system specific, or disease specific, 
all of which have been used to assess quality of life in patients with glaucoma. 
General health-Related PROMs: These measures are typically used to assess the 
effects of interventions and vision loss on quality of life. An important benefit of these 
instruments is they allow for an overview of health which can be compared to other 
diseases. An example of a general health-related PROM is The Medical Outcomes Study 
Short-Form Health Survey (SF-36) (Ware & Sherbourne, 1992) which measures patients’ 
health perceptions in a number of areas – general health, physical function, role 
limitations due to physical and mental disability, social function, vitality, mental health, 
and bodily pain. The sensitivity of the SF-36 at detecting treatment effects and disease 
progression is assessed in a later chapter of this thesis. 
Vision-specific PROMs: Initially, the primary goal of vision-related quality of life 
instruments was to assess the effect of cataract on patients’ perceived visual function 
(Mangione et al., 1992). Vision-specific PROMs are now widely used in various aspects of 
ophthalmic research (Glen et al., 2011; Hamzah et al., 2011). These PROMs assess ocular 
symptoms and specific difficulties with tasks which rely on vision. Questions relating to a 
similar theme are often grouped into subscales. For example, questions such as ‘Because 
of your eyesight, how much difficulty do you have seeing how people react to things you 
say?’ and ‘Because of your eyesight, how much difficulty do you have visiting with people 
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in their home, at parties, or in restaurants?’ are often used to assess the subscale of Social 
Functioning. Vision-specific PROMs are likely to provide more clinically useful 
information about the impact of the disease on the patient, but do not allow for 
comparison with non-ocular disease states (Spratt et al., 2008). A commonly used vision-
related quality of life instrument, the National Eye Institute visual functioning 
questionnaire (NEI VFQ-25), is used to assess the impact of visual functioning in Chapter 
2 of this thesis. 
Glaucoma-specific PROMs: These instruments were developed to better 
discriminate between patients with glaucoma from individuals with healthy vision. 
Glaucoma-specific PROMs are more likely to correlate with visual field loss in patients 
with glaucoma than instruments relating to general health (Spaeth et al., 2006). 
Questions typically relate to visual ability, task performance, and the impact of reduced 
visual ability on the patient. An example of a glaucoma-specific PROM, the Glaucoma 
Quality of Life (GQL-15) is shown in Figure 1.6. The GQL-15 has previously been found to 
demonstrate discernible differences between glaucoma patients with mild visual field 
loss compared to control individuals (Nelson et al., 2003). This finding challenges the 
belief that glaucoma is an asymptomatic disease in its early stages. The sensitivity of 
glaucoma-specific PROMs at detecting changes in disease-state is assessed in Chapter 3 
of this thesis. 
Indeed, asking a patient directly is an effective way to ascertain how they feel 
about their condition and how it might be affecting their well-being (Deshpande et al., 
2011). However, a fundamental problem with PROMs is that they are subjective, and no 
single instrument covers all aspects of patients’ vision-related quality of life (Somner et 
al., 2012).  As such, using PROMs to assess how glaucomatous visual loss is affecting 
patients can be problematic, especially as the disease is often asymptomatic. However, 
PROMs are now being used as primary outcome measures in glaucoma clinical trials 
(Azuara-Blanco et al., 2016; King et al., 2017; Vickerstaff et al., 2015) and there is good 
rationale for using outcomes that are directly relevant and meaningful to the patient. Yet, 
it is possible that PROMs are not as sensitive to changes in visual function as clinical 
measures of functional loss, like automated perimetry. As such, it is proposed that the 
sensitivity of PROMs when used in glaucoma trials is examined and this is the focus of 
Chapter 3 in this thesis. 
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Figure 1.6: An example of a patient-reported outcome measure where 15 items use a 6-point Likert scale 
for individual responses. This figure was reproduced from Nelson et al., (2003). 
 
1.6.3 Vision-related quality of life in glaucoma 
It is important to assess the impact of glaucoma on vision-related quality of life for all 
patients with the disease. Insight into how glaucoma affects vision-related quality of life 
might offer a means of developing treatment strategies tailored towards the individual's 
needs. It has been shown that good vision is valued much more highly than clinicians 
realise (Brown et al., 2006) and that ophthalmologists frequently underestimate the 
impact of glaucoma on the patient’s life (Brown et al., 2000). An understanding of how 
glaucoma impacts on the lives of patients and their families can alert clinicians to 
potential strategies to help ease the burden of the disease. For example, knowledge that 
glaucoma patients may have greater difficulty under poor light conditions may prompt 
evaluation of the patient’s home, whereby lifestyle suggestions can be made, such as 
ensuring suitable lighting or minimise obstacles (Livengood & Baker, 2015). Furthermore, 
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an understanding of vision-related quality of life in the later stages of the disease may 
help to educate other patients about the possible future impact of glaucoma on their 
lives (Newsham et al., 2007). In addition, knowledge of when daily tasks become affected 
by glaucomatous visual loss may have a key role in determining when to begin treating 
the patient, or making changes to current treatment plans. As the main aim when treating 
glaucoma is to maintain vision-related quality of life, having an understanding of how a 
decline in visual function can negatively impact the patient’s life is imperative. Research 
into the association between glaucoma and vision-related quality of life is often 
disjointed and has produced conflicting results. For that reason, this thesis (Chapter 2) 
aims to further explore this relationship and provide new insights into the knowledge of 
vision-related quality of life and glaucoma. 
1.7 Visual disability 
Visual function can relate to many aspects of daily living where having good vision can 
determine how well a task can be completed. Studies have highlighted that pathologies 
which affect vision, such as glaucoma, can affect a broad array of activities (Gutierrez et 
al., 1997; Mills et al., 2001; Parrish et al., 1997; Ringsdorf et al., 2006). When assessing 
visual function in people with eye disease, it is important to consider how the disease 
impacts ability to complete activities that are most important to individuals, as well as 
activities that are most likely to be affected by the disease (Ramulu, 2009). Growing 
emphasis is now being placed on the self-reported visual function of individuals with 
glaucoma. This is, at least in part, due to recent guidelines set by the European Glaucoma 
Society (EGS) which states that maintaining patients’ vision-related quality of life is 
paramount when treating glaucoma (EGS, 2017).  
1.7.1 Visual disability in glaucoma 
There is good clinical evidence to indicate that vision-related quality of life is impaired in 
patients with glaucoma (Janz et al., 2001; Spaeth et al., 2006). Deterioration in visual 
function has a major influence on vision-related quality of life related to glaucoma 
(Medeiros et al., 2015). Reductions in vision-related quality of life have been specifically 
attributed to the progressive loss of visual field (McKean-Cowdin et al., 2008; Hyman et 
al., 2005). Research has focused on establishing which specific tasks may be most affected 
in glaucoma (Glen et al., 2011). Many of these tasks would be routine activities for the 
patient, and so a decrease in ability, or a total inability, to perform these tasks can have 
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significant consequences for the patient’s vision-related quality of life. It has previously 
been suggested that the impact of visual disability on vison-related quality of life is 
unlikely to be a linear relationship (Peters et al., 2015). This is because many daily tasks 
can still be performed in the early stage of glaucoma, however these tasks become more 
difficult to achieve as the disease advances. Rather, there is likely to be a visual disability 
‘threshold’ where vision-related quality of life will decline more rapidly once routine tasks 
can no longer be performed. The concept of a visual disability threshold is further 
investigated in this thesis (see Chapter 2). 
The following sections will consider some of the most common visual function-
related difficulties experienced by patients with glaucoma. 
1.7.2 Lighting conditions 
Patients with glaucoma frequently report difficulty when adjusting to different light 
intensities or glare (Burr et al., 2007; Nelson et al., 1999). Specifically, having difficulty 
with glare and light adaptation have been ranked as the most problematic symptom of 
glaucoma; more so than trouble with mobility, reading, and socialising (Nelson et al., 
1999). Case-control findings suggest glaucoma patients are more likely to report 
difficulty with glare and lighting adaption compared to healthy-sighted observers (Lee 
et al., 1998; Sherwood et al., 1998). Interview and questionnaire studies have highlighted 
that problems with glare and lighting are frequently reported in patients with even mild 
stage glaucoma (Burr et al., 2007). Glaucoma suspects with impaired scotopic vision are 
more likely to have signs of early optic nerve injury (Glovinsky et al., 1992), suggesting 
that difficulty with light adaption may be one of the earliest symptoms presented in 
patients with glaucoma. It is in the domain of lighting and glare that the greatest change 
in self-reported disability occurs as glaucoma worsens (Burr et al., 2007; Nelson et al., 
1999). This would suggest that difficulty with lighting and glare becomes more profound 
in the moderate and advanced stages of the disease. 
Few studies have specifically investigated the role of lighting conditions on task 
performance in glaucoma. In a review of glaucoma-related disability, Ramulu highlighted 
that the lighting conditions under which tasks are performed may be more important 
than the task itself (Ramulu, 2009). Yet, this aspect of glaucoma disability remains largely 
unexplored.  
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1.7.3 Reading 
With the exception of such tactile writing systems as Braille, reading is an example of a 
routine activity that relies entirely on vision. Typically, reading refers to the ability to read 
text at close range, as with reading a book, and so requires good near vision. However, 
ability to read may not solely rely on near vision, but also reading at greater distances, 
such as with reading road signs, text on television, and bus numbers. When reporting on 
reading ability, studies tend to assess the ability to read at near distances. Difficulty with 
near vision is common among visually impaired patients (Burr et al., 2007), and problems 
with reading are frequently reported among patients with glaucoma (Mangione 1998; 
Freeman, 2008; Parrish et al, 1997; Sherwood et al., 1998). The magnitude of reading 
difficulty is a concern given the high level of importance patients with glaucoma give to 
this everyday task (Burr et al., 2007).  
 Reading ability is often determined based on the patient’s own perception of their 
reading speed. Yet, self-reported reading speed and actual performance may not 
correlate (Friedman et al., 1999). Few studies have directly investigated the impact of 
glaucoma on actual reading ability. In patients with bilateral visual field loss, reading 
speed has been found to be reduced when completing both silent and out-loud reading 
tasks compared to controls (Ramulu et al., 2013; Burton et al., 2014). In addition, 
prolonged periods of reading can incur greater fatigue among glaucoma patients 
(Nguyen et al., 2014), possibly attributed to the increased saccadic frequency and a 
tendency to lose fixation (Burton et al., 2014). 
1.7.4 Mobility, balance, and driving 
Mobility is a key component to living an independent lifestyle and so, not surprisingly, 
patients with reduced vision place high value on having good mobility (Aspinall et al., 
2008). There are a wide variety of daily tasks where mobility has an essential role, such 
as grocery shopping and moving up and down steps. Mobility is strongly correlated with 
glaucomatous visual field loss (Friedman et al., 2007; Viswanathan et al., 1999; Black et 
al., 2011) and patients with glaucoma are more likely to suffer injuries from falls 
compared to individuals with healthy vision (Haymes et al., 2007).  Moreover, glaucoma 
patients usually have slowed walking speeds (Turano et al., 1999), which may in part be 
due to a higher level of concentration required to avoid hazards. 
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 Studies indicate that glaucoma appears to be associated with impaired balance. 
It has been reported that patients with glaucoma have increased postural instability when 
performing objective assessments of balance (Black et al., 2008) and binocular mean 
deviation has been shown to be a significant predictor of balance ability (Kotecha et al., 
2012). While visual inputs are an important attribute for a good sense of balance, there 
are a number of systems which contribute towards postural stability, where a complex 
interaction between the vestibular, somatosensory, and visual systems is required 
(Massion, 1994). Yet, when performing balance related assessments with eyes closed, 
glaucoma patients perform similarly to control patients (also with eyes closed) (Shabana 
et al., 2005), indicating that loss of vision is a key factor in worsening balance among 
glaucoma patients. 
In addition to reduced walking speed and higher likelihood of falls, impaired 
mobility and balance can result in social isolation and be detrimental to overall general 
health. One study found that patients with glaucoma are more likely to avoid going 
outdoors, possibly due to fear of injury (Ramulu et al., 2012) and avoidance of outdoor 
activities was found to increase as glaucomatous visual field loss worsens. In addition, a 
reduction in physical activity has been linked with a host of chronic diseases including: 
diabetes, cancer, osteoporosis, and disorders affecting the cardiovascular system 
(Warburton et al., 2006). 
The transportation of choice for many older adults is driving (Eberhand, 1998) 
and therefore is a key component of mobility. Diseases which impair functional ability, 
such as glaucoma, can make it difficult for patients to continue to be safely mobile. Loss 
of driving ability is one of the most feared aspects for patients diagnosed with glaucoma 
(Bhargava et al., 2006), and a significant proportion of people with glaucoma will be 
declared as unfit to drive (Ang & Eke, 2007). Loss of driving license can have a 
considerable impact on quality of life due to its ramifications on social independence and 
self-esteem. Indeed, elderly people who have stopped driving are at risk of worsening 
depressive symptoms (Fonda et al., 2001) and are more likely to stay indoors (Marottoli 
et al., 2000), or be moved into long-term care (Freeman et al., 2006). For patients still 
driving, glaucoma can pose significant problems, including more self-reported difficulty 
when driving (Freeman et al., 2008) and more likely to be involved in traffic accidents 
(Szlyk et al., 2005). 
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1.7.5 Visual search and face recognition 
Visual search refers to the ability to pick out a specific object in a scene, such as locating 
an item on a supermarket shelf. Visual search is an example of a routinely performed task 
where visual ability plays a key role. Glaucoma patients report difficulties when searching 
for specific objects, especially in cluttered environments (Goldberg et al., 2009; Nelson et 
al., 2003). Objective assessment of visual search ability may offer a more clinically useful 
indication of visual disability among patients with glaucoma (Crabb & Taylor, 2017). 
Studies adopting a more objective assessment of visual search ability show that the time 
taken to complete real-world search tasks suggest that glaucoma patients have greater 
difficulty when searching for objects compared to age-matched controls (Smith et al., 
2012; Smith et al., 2011). 
Qualitative research has indicated that patients with glaucoma can struggle to 
identify faces, such as characters on television or friends and neighbours in the street 
(Glen & Crabb, 2015). There is evidence to suggest individuals with advanced glaucoma 
may have more difficulty with recognising faces than healthy-sighted peers (Glen et al., 
2012). Problems with face recognition have been found to have long-term effects, 
whereby patients may begin to avoid social situations and can have difficulty in gaining 
employment (Yardley et al., 2008).  
1.8 Patient journey in glaucoma 
As discussed previously (see section 1.6.2), glaucoma can have a significant impact on 
patients’ vision-related quality of life. Glaucoma will mainly affect quality of life through 
visual disability, whereby routine activities become progressively more difficult to 
complete and restrict individuals’ ability to live an autonomous life. However, glaucoma 
can negatively influence quality of life in numerous ways, including the burden of 
ongoing therapy and hospital visits, unpleasant side effects of treatment, anxiety 
associated with living with a chronic disease, and fear of future visual loss (Janz et al., 
2007; Wu et al., 2011). 
 The concept of the ‘patient journey’ for those living with chronic conditions has 
garnered increased attention in recent years. The British Medical Journal (BMJ) has 
published a number of commentary articles whereby patients have detailed their 
personal journey of living with chronic illnesses (Lapsley & Groves, 2004), including 
stories of Parkinson’s disease, dementia, and also glaucoma (Baker & Graham, 2004; 
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Dartington, 2008; Hartmann & Rhee, 2006). The aim of these such articles is to describe 
the difficulties faced when diagnosed with a chronic condition and how this impacts on 
quality of life. Stories of the patient journey can be a rich source of knowledge which can 
facilitate an understanding between patients and healthcare professionals, beyond that 
offered by clinical examination or formal case history (Lapsley & Groves, 2004). As such, 
stories of the patient journey can advise others of what really matters to the patient, and 
what can be done to help. Hartmann and Rhee give an explicit insight into the subjective 
experience of the journey as a patient with glaucoma. Notably, the authors discuss the 
burden of frequent visits to eye clinics and the distress of non-effective medication and 
surgery.  
Qualitative research has considered the impact of glaucoma to be on a spectrum, 
whereby the earliest stage, as well as the later more advanced stage of the disease, 
represent particularly challenging time points in the glaucoma patient journey (Cross et 
al., 2009). This concept of the glaucoma impact ‘spectrum’ makes clinical sense as, in the 
earliest stages, the patient must come to terms with living with a chronic disease, the 
burden of hospital visits and medications, and the fear of worsening functional ability. 
For late-stage disease, these patients have experienced unprecedented psychological 
challenges such as worsening vision and a decline in visual ability, and the ordeal of 
invasive and possibly fruitless surgical intervention. The aim of this thesis is to shed 
further light onto the patient journey in glaucoma and to understand the impact of the 
disease on patients’ quality of life. Because it is rational to consider the impact of 
glaucoma on a spectrum, this thesis will pay particular attention to the stages of the 
disease which are likely to have the greatest impact on the patient – the early and late 
stages of glaucoma. 
1.9 Rationale and aims of PhD 
In order to better understand the impact of glaucoma, it is necessary to conduct 
evidence-based research to investigate how the disease affects the patient’s daily life. 
Such research may help to promote awareness of the disease and can serve as an 
important resource for improving the patient journey in glaucoma. Aspects of the patient 
journey investigated in this thesis relate to a number of key issues in the field of glaucoma 
and ophthalmology. Specifically, the following aims were investigated: 
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1. To investigate the relationship between vision-related quality of life and 
clinically measured visual function. Vision-related quality of life is a pivotal component 
to good overall wellbeing. The hypothesis was that individuals with glaucoma will self-
report different levels of vision-related quality of life depending on the severity of their 
disease. Results are discussed in the context of previous vision-related quality of life 
research in glaucoma (see Chapter 2). 
2. To assess quality of life measures when used with patients recruited to The 
United Kingdom Glaucoma Treatment Study. Patient-reported outcomes play a 
significant role in clinical trials. This study examined glaucoma patients’ responses on a 
number of frequently used PROMs and assessed whether such instruments are 
appropriate to be used as primary outcome measures in clinical trials. In addition to 
enhancing our understanding of the impact of glaucoma in the early stages of the 
disease, this study may have implications for the design of future clinical trials in 
glaucoma (see Chapter 3). 
3. To examine a novel service for monitoring glaucoma patients in the hospital eye 
service. This study audited a virtual glaucoma monitoring service with the use of a ‘big 
data’ approach. Results are discussed in relation to how novel monitoring systems may 
help to reduce the burden glaucoma may have on patients and their caregivers and how 
this may have a subsequent impact on quality of life (see Chapter 4). 
4. To understand the patient and surgeon perspectives of high-stakes surgical 
intervention in advanced glaucoma. For the study described in this chapter, individuals 
with experience of ‘only-eye’ surgery were interviewed about their thoughts of glaucoma 
surgery performed on individuals with only one functioning eye. Both patients and 
surgeons were asked to recall their experiences of these high-stakes procedures using 
semi-structured interviews. Interview transcripts were thematically analysed and 
generated a number of key themes relevant to only-eye surgery. The results of this study 
highlight the challenges to overcome when caring for patients with advanced glaucoma 
(see Chapter 5). 
Chapter 6 gives a summary of the main findings from these research studies and are 
discussed in the context of the implications for individuals living with glaucoma and 
potential areas for future work.  
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Chapter Two - The relationship between loss of visual field and vision-related 
quality of life 
Glaucoma will impact the daily life of a patient with the disease. If a person’s glaucoma 
is not clinically stable, the disease can progress and can cause increased visual disability 
(Ramulu, 2009). However, visual disability is not the only reason for decreases in 
glaucoma patients’ wellbeing and vision-related quality of life. Rather, causes for decline 
in vision-related quality of life are multifactorial and include the burden of ongoing 
therapy, unpleasant side effects of medication, stress of ongoing treatment, fear of 
further visual loss, strain on informal care givers, and burden of repeated clinic visits for 
disease monitoring. As expected, the psychological burden of glaucoma increases as 
vision decreases, along with a growing fear of blindness and visual disability (Janz et al., 
2007), and an increase in depressive symptoms (Wang et al., 2012). The purpose of this 
chapter was to analyse the impact of glaucoma on vision-related quality of life among 
patients with a range of disease severity. The aim was to achieve a greater understanding 
of the patient journey in glaucoma by highlighting stages where glaucoma might have 
the greatest impact on the patient. 
 The work presented in this chapter has formed a paper published in Journal of 
Ophthalmology (Jones et al., 2017); see list of supporting publications. The co-authors of 
this work are David Crabb (DC) and Susan Bryan (SB). Help with the spline-fitting method 
of data analysis, data visualisation, and calculation of the Akaike Information Criterion 
(AIC) came from SB and DC. Data were collected by Prior et al., 2013 as part of the pilot 
Aberdeen Glaucoma Questionnaire (AGQ) study. Access to the data was approved by 
Jennifer Burr (JB). The AGC study is a component of a Medical Research Council funded 
strategic grant, G0701759: Developing the intervention and outcome components of a 
proposed randomised controlled trial of a national screening programme for open angle 
glaucoma. Data analysis was performed by Lee Jones (LJ). The paper was written by LJ, 
and reviewed, edited, and approved by SB and DC. 
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2.1 Introduction 
The loss of visual field sensitivity is hallmark in patients with glaucoma (Crabb, 2016). This 
loss in sensitivity can pose as a signiﬁcant threat to patients’ everyday functioning and 
quality of life. It is often the case that glaucoma patients report greater diﬃculty in 
performing vision-related tasks as the severity of the disease increases and the damage 
to the visual field worsens (Ramulu, 2009; Jampel et al., 2002; van Gestel et al., 2010; 
Gutierrez et al., 1997; Parrish et al., 1997; McKean-Cowdin et al., 2007). However, it is not 
uncommon for the eﬀects of glaucoma to go undetected by the patient (Crabb, 2016; 
Quigley & Broman, 2006). For example, many performance-based studies demonstrate 
that glaucoma patients can perform within the normal expected range, even in cases of 
advanced visual field loss (Burton et al., 2014; Smith et al., 2012; Smith et al., 2011; 
Kotecha et al., 2009; Glen et al., 2012). Conversely, there is evidence to suggest that even 
mild or moderate glaucomatous disease may have an impact on the patient’s quality of 
life (Alqudah et al., 2016). 
Assessment of vision-related quality of life typically involves self-reported 
response to questionnaires. These questionnaires, also referred to as ‘instruments’, 
feature items whereby patients mainly document the extent to which they struggle to 
complete routine tasks. The NEI VFQ-25 (Mangione et al., 2001) has been widely used in 
ophthalmology research as a measure of vision-related quality of life.  This instrument 
was used in a landmark report revealing the association between visual field loss and 
health-related quality of life in glaucoma (McKean-Cowdin et al., 2007), and has been 
widely used in other cross-sectional studies (Jampel et al., 2002; van Gestel et al., 2010; 
Gutierrez et al., 1997; Parrish et al., 1997; Alqudah et al., 2016; Mills et al., 2001; Sumi et 
al., 2003). However, these studies report only a modest relationship between vision-
related quality of life and visual field damage. More recently, longitudinal studies of 
glaucoma patient cohorts have highlighted NEI VFQ-25 scores to be impacted by 
location and speed of visual field loss. (Abe et al., 2016; Medeiros et al., 2015; Gracitelli 
et al., 2015). 
Association between visual field loss and worsening of vision-related quality of 
life reported in the literature mainly implies that the relationship is a linear one (McKean-
Cowdin et al., 2007; Alqudah et al., 2016; Abe et al., 2016; Medeiros et al., 2015). That is, 
vision-related quality of life constantly declines as the visual field worsens. In fact, the 
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relationship between loss of vision-related quality of life and visual field worsening is 
likely better described as a monotonic one.  In other words, whilst vision-related quality 
of life never improves as the visual field worsens, the decline could have slow or rapid 
stages, or even remain relatively constant for a phase. This idea, relatively unexplored, is 
the subject of this study. 
Patients with glaucoma are typically asymptomatic in the early stages of the 
disease process. Any change in visual field status may be compensated for by good 
binocular vision or is simply not noticed. As visual field loss becomes symptomatic a 
patient is more likely to self-report an impact on vision-related quality of life, but in turn 
patients may adapt to their vision loss.  Indeed, there is some evidence that behavioural 
adaptions, such as adjusted head and eye movements, can help glaucoma patients 
compensate for their vision loss when completing everyday tasks (Burton et al., 2014; 
Smith et al., 2012a; Glen et al., 2013; Smith et al., 2012b; Crabb et al., 2014; Glen & Crabb, 
2015; Hassan et al., 2015). Eventually as glaucoma worsens, visual field loss will likely 
impact on legality of driving and restrict mobility and confidence (Glen & Crabb, 2015; 
Hassan et al., 2015; Friedman et al., 2007; Kotecha et al., 2012; Black et al., 2011; Yuki et 
al., 2013; Ramulu et al., 2012; Ramulu et al., 2014). 
Patients with more advanced glaucoma report significantly worse scores on the 
NEI VFQ-25 compared to their better sighted peers. In a cross sectional analysis of an 
established cohort of 233 patients from the Early Manifest Glaucoma Trial (EMGT) (Heijl 
et al., 2002), Peters and colleagues hinted at the idea of accelerated worsening of vision-
related quality of life once patients reach a certain visual field threshold (MD of -18dB or 
worse) in their least affected or ‘better’ eye (Peters et al., 2015). This evidence suggests a 
‘tipping point’ after which each decibel of visual field loss will have more severe 
consequences for patients’ vision-related quality of life. This observation is worth further 
study. Thus, the purpose of this study was to investigate the relationship between vision-
related quality of life (using NEI VFQ-25 scores) and a summary measure of visual field 
loss (the MD) amongst a spectrum of disease severity in a large number of patients from 
a glaucoma clinic. Specifically, we consider that the rate of decline in vision-related 
quality of life may not simply be a linear process and we look for statistical evidence of 
different phases of decline or periods where there might be more or less rapid reduction 
as the visual field worsens. 
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2.2 Methods 
This study took advantage of anonymised patient data collected as part of an 
investigation of conducting a randomized controlled trial for glaucoma screening in the 
United Kingdom (UK) (Burr et al., 2014). The data, collected from a cross-sectional postal 
survey, is described in detail elsewhere (Prior et al., 2013) but is also summarised below. 
Potential participants were identified by an ophthalmologist from an electronic 
patient record (Medisoft, Leeds, UK) of visual fields at a hospital based glaucoma service 
in London (Moorfields Eye Hospital NHS Foundation Trust). Recruitment criteria required 
potential patients to have at least two entries in the database having undergone visual 
field testing on a Humphrey Visual Field Analyser (HFA; Carl Zeiss Meditec, CA, USA) 
between January 2007 and September 2009. To be included, patients were required to 
have reproducible HFA 24-2 (SITA Standard) visual field defects in both eyes at the two 
most recent visits as determined by the Glaucoma Hemifield Test (GHT) (Åsman & Heijl, 
1992). The GHT results had to be “borderline” or “outside normal limits” as recorded in 
the electronic patient record on both occasions. A total of 1349 patients were considered 
as suitable for study recruitment. Ethical approval was granted and the study adhered to 
the Declaration of Helsinki.  
 Questionnaires were posted to all patients considered suitable for the study in 
March 2010. Included with the questionnaire was a participant information sheet, a letter 
of invitation from their consultant ophthalmologist, and a reply paid envelope. The postal 
questionnaire comprised of four elements: a pilot instrument of the Aberdeen Glaucoma 
Questionnaire; a measure of overall general health (EQ-5D); questions relating to 
baseline demographics; and the vision-specific PROM, the NEI VFQ-25 (Mangione et al., 
2001). This instrument consists of 25 items across 12 subscales, where 11 constructs are 
vision-related (General Vision, Ocular Pain, Near Activities, Distant Activities, Social 
Functioning, Role Difficulties, Mental Health, Dependency, Driving, Colour Vision, and 
Peripheral Vision) and one construct regarding general health. A reminder letter was sent 
two weeks after initial contact. No further contact was made with those who did not 
return the questionnaire. The return of completed questionnaires was considered as 
consent to take part in the study. A total of 656 questionnaires were returned. Ethics 
committee approval was obtained for the study from the North of Scotland Research 
Ethics Committee (Ref: 09/S0802/107). For those returning the questionnaire, we 
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obtained data from the visual field databases on visual field parameters, mean defect 
and pattern standard deviation. 
The HFA MD in the least affected eye (Best eye MD; BEMD) recorded at the most 
recent clinical visit to when the questionnaire was administered was used as the surrogate 
measure of visual field loss. The MD is conventionally used in the clinic and in clinical 
trials; it is a summary measure of the overall reduction in visual field sensitivity relative 
to a group of healthy age-matched observers, with more negative values indicating more 
vision loss. We used the BEMD since this best reflects the patients’ visual field morbidity 
(Arora et al., 2013). Numeric responses on the NEI VFQ-25 were re-coded in line with the 
scoring guidelines (Mangione et al., 2001). Each item is converted into a value ranging 
from 0 to 100 where higher scores indicate greater vision-related quality of life and lower 
scores indicative of poorer vision-related quality of life. A composite score for vision-
related quality of life was then calculated by averaging all vision-related subscales. In 
cases where more than 5% of the questionnaire data were missing, or where subscale 
scores were unable to be calculated due to insufficient data, responses were excluded 
from our analysis.  In line with scoring guidelines, patients who had never driven a car 
had responses coded as ‘missing’ for the driving subscale (Mangione et al., 2001). 
A total of 636 patients with complete NEI VFQ-25 and BEMD data were used for 
this analysis. No other data, apart from age (years) at the time of the most recent visual 
field, was considered. 
We explored the relationship between BEMD and NEI VFQ-25 using the 
freeknotspline package in the statistical programming language R (www.R-project.org). 
This package fits free-knot splines to data with one independent variable and one 
dependent variable (Spiriti et al., 2013; Montoya et al., 2014). This technique will 
automatically highlight phases where a monotonic relationship between two variables 
may change. The points where the phases (segments) connect are called the knots of the 
spline. Knots can be determined a priori or by allowing the data to dictate areas where 
change occurs. A knot-search algorithm is provided for the case where the number of 
knots is not known in advance, as with these data. In the subsequent analysis it is then 
possible to compare the spline model that describes this relationship against a linear 
relationship (using ordinary least squares regression [OLSR]) by considering the Akaike 
information criterion (AIC); this is a measure of the relative quality of statistical models 
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for a given set of data, and provides a means for model selection (Akaike, 1976). Phases 
in the relationship between BEMD and NEI VFQ-25 identified by this approach were then 
further analysed using linear OLSR where a series of separate OLSR lines are fitted to 
appropriate ranges of BEMD. These analyses, including plotting the data, were performed 
in R (www.R-project.org) and SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for 
Windows, Version 23.0. Armonk, NY: IBM Corp). 
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2.3 Results 
Median (interquartile range; IQR) age of the 636 patients analysed was 70 (60, 77) years. 
Median (IQR) BEMD was -2.1 (-5.2, -0.4) dB and worst eye MD was -5.5 (-11.3, -2.3) dB. 
Median (IQR) composite score on the NEI VFQ-25 was 89 (74, 95) points. The majority of 
patients (97%) scored their general health to be good or better on the general health 
item of the NEI VFQ-25.  
Figure 2.1 shows the distribution of patients’ BEMD score against composite 
scores from the NEI VFQ-25. The red line (left-hand side plot) gives the best-fitting linear 
OLSR line (red line). This model assumes a linear association between BEMD and NEI 
VFQ-25. The blue line (right-hand side plot) shows the automatically chosen penalised 
spline model which had two knots with a polynomial of degree 3.  
 
Figure 2.1: Points represent scores on NEI VFQ-25 compared to BEMD (dB) for 636 patients. The use of linear 
(red line) and spline (blue line) regression modelling assessing trend in relationship between the two 
variables. 
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The AIC index for the linear and spline models was 3601.7 and 3596.0 respectively. 
In simple terms the AIC index indicates stronger evidence for a preference of one model 
over another (the lower the better). There is some debate in the applied statistics 
literature about the meaning of small differences in AIC, but differences >5 (as with these 
data) indicate that the model with the lower AIC is likely to be more informative (Symonds 
& Moussalli, 2011). For the purposes of this study, this statistical interrogation of the 
relationship mainly suggests defined phases where NEI VFQ-25 deteriorates with more 
or less acceleration as a patient’s BEMD worsens.  On inspection there seems to be three 
phases in the association. For BEMD up to about -5dB there is a distinct slope followed 
by a phase (between -5 dB and -15dB) where the line flattens before it becomes much 
steeper again (worse than -15dB). Three OLSR lines were fitted to these three phases and 
the results along with 95% confidence limits are shown in Figure 2.2 with model 
parameters given in Table 2.1. Simply put, the average patient loses about 2 units (out of 
100) on NEI VFQ-25 for every loss of 1 dB (BEMD) as their glaucomatous visual field loss 
become bilateral, up to -5dB. Worsening on NEI VFQ-25 then appears to slow down: the 
average patient loses about 1 unit (out of 100) on NEI VFQ-25 for every loss of 1 dB 
(BEMD) from -5 to -15dB. Finally, a more rapid phase of deterioration in vision-related 
quality of life seems to occur: after the BEMD worsens to around -15dB the average 
patient starts to lose 4 to 5 units on NEI VFQ-25 for every remaining loss of 1 dB (BEMD). 
Table 2.1: Relationship between decline in NEI VFQ-25 score for piecewise regression analysis for each 1dB 
decline in BEMD score. 
 
BEMD 
(dB) 
N Slope (95% 
Confidence interval) 
Standard 
error 
p-value 
+2 to -5 (Yellow) 475 2.3 (1.5,3.0) 0.40 <0.001 
-5 to -15 (Green) 132 1.1 (-0.3,2.5) 0.70 0.14 
< -15 (Red) 29 4.6 (1.2, 8.0) 1.64 0.009 
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Figure 2.2: Fitting of three OLSR lines with 95% confidence limits for each phase of decline in vision-related 
quality of life. Points represent scores on the NEI VFQ-25 and BEMD in 636 patients. The green phase shows 
the slowest decline in NEI VFQ-25 score, the yellow line shows quicker decline where NEI VFQ-25 scores 
reduce 2 times faster than in the green phase. The red line shows decline on NEI VFQ-25 as about four times 
quicker than in the green phase. 
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2.4 Discussion 
Economists anecdotally refer to bankruptcy happening in two stages – gradually then 
suddenly (Taylor, 2015). Hence, a monotonic process but not necessarily a linear one. In 
this study we provide some evidence that this is what happens in patients’ perception of 
their vision-related quality of life as their glaucomatous visual field worsens in their better 
eye over time. Rather than a linear decline we suggest there are phases of change 
attributed to progression in the visual field in the least affected eye. The phases illustrated 
in the statistical associations we report make clinical sense. As the better-seeing eye gets 
measurable visual field loss (bilateral disease) the previously asymptomatic patient may 
begin to notice the impact of scotoma as they perform visual tasks. A phase of adaptation 
to this loss then might likely precede another phase where advanced loss in both eyes 
really impacts on vision-related quality of life. Our evidence isn’t strong; it is merely based 
on a cross-sectional survey of people from glaucoma clinics with no supplementary 
clinical information. Yet our results support a concept that ought to be tested with other 
datasets or longitudinal studies. Better knowledge on how visual function decline may 
accelerate at different stages of the disease process would be useful for the clinical 
management of patients and also for health economists as they determine better utilities 
for evaluating glaucoma treatments. 
 Our findings add to current understanding of how patients perceive their 
difficulty living with glaucoma. Vision-related quality of life deteriorates as glaucoma 
worsens and our data supports this. This association is not particularly a strong one. For 
example, the R-squared (%) for the linear association between vision-related quality of 
life and BEMD data is 21% suggesting that only part of the variance in vision-related 
quality of life is explained by the visual field. Moreover, it is quite remarkable how some 
patients with BEMD worse than -20dB (top left hand corner of graph depicted in Figure 
2.2) report vision-related quality of life to be the same or better than many patients with 
a BEMD of 0 dB or higher. This observation coincides with the findings of others 
indicating only a modest relationship between NEI VFQ-25 scores and visual field status 
(Jampel et al., 2002; van Gestel et al., 2010; Gutierrez et al., 1997; Parrish et al., 1997; 
Alqudah et al., 2016; Mills et al., 2001; Sumi et al., 2003). Our statistical treatment of our 
large cross-sectional data implies that this weak association may behave differently at 
different stages of BEMD severity and this is new knowledge.  Our findings give some 
weight to the idea that the speed at which vision-related quality of life declines may alter 
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during different phases of the disease and that specific markers for BEMD could indicate 
change points in patient-reported functional ability. 
 Our observations of different phases of association between vision-related quality 
of life and BEMD are supported by the results from a twenty year follow up of patients 
in the EMGT (Peters et al., 2015). In a cross sectional analysis of this cohort of 233 patients, 
Peters et al. found a significant difference in Rasch-calibrated scores on the NEI VFQ-25 
for patients with BEMD worse than -18 dB and those with BEMD better than -18 dB. In 
cases where BEMD was worse than -18 dB, patients’ scores on the NEI VFQ-25 did not 
exceed 70 out of 100. This suggests different phases in the relationship between BEMD 
and NEI VFQ-25, with a threshold where impact of visual field loss accelerates. A strength 
of this study is that a wide range of glaucoma severity was analysed, whereas other 
studies consider only patients with early glaucomatous damage (Jampel et al., 2002; 
Alqudah et al., 2016).  
 In addition to supporting the concept of a non-linear relationship between vision-
related quality of life and BEMD, our results also support recent findings regarding the 
impact of glaucoma on vision-related quality of life in the earlier stages of the disease. 
Our results indicate that a 1 dB decline in BEMD is associated with an average reduction 
of 2.3 units on the NEI VFQ-25 for patients with BEMD between +2 dB and -5 dB. This 
finding is similar to that of a longitudinal study by Alqudah et al. (2016) who found an 
association between scores on the NEI VFQ-25 and BEMD in the early stages of 
glaucoma. Their study was restricted to patients with BEMD between approximately +2.5 
dB and -5 dB and they reported a decline of 0.5 units on the NEI VFQ-25 for each 1 dB 
reduction. 
 Our findings become important when considering treatment options for patients 
with advanced stage glaucoma. It is evident that patients’ vision-related quality of life 
reduces rapidly once BEMD loss becomes advanced. Decline in vision-related quality of 
life is approximately four times faster than in previous stages of the disease after patients’ 
vision deteriorates beyond -15dB. This threshold may have important clinical implications 
when treating patients in the advanced stages of the disease. Due to the potential for 
fast decline in vision-related quality of life, this point could be used to guide potential 
intervention options when treating patients with advanced glaucoma. The suggestion 
has been made that more research is needed in order to determine the best treatment 
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option for advanced glaucoma (King et al., 2011), and this is currently under investigation 
in a randomised clinical trial (King et al., 2017). Our results may also have implications for 
those developing utilities for health economic models for glaucoma treatments 
(Boodhna & Crabb, 2016). 
 There are some strengths to our study.  The sample size was large and we took 
advantage of a large database of recorded visual field data. These data represent 
unselected people in glaucoma clinics that are receiving routine care and therefore 
estimates are directly meaningful to ‘real-world’ practice. In addition, the patients in this 
study had a wide range of glaucoma severity. However, the proportion of patients with 
early visual field damage was greater than advanced cases and this could be perceived 
as a limitation.  
Our investigation also had some limitations. The data used is cross-sectional and 
so we only consider patients’ vision-related quality of life and visual field loss at a single 
time point. Moreover, measures of vision-related quality of life are self-reported. We are, 
for example, unable to account for the rate at which patients’ visual field defect has 
progressed - and this has been shown to influence vision-related quality of life (Medeiros 
et al., 2015; Lisboa et al., 2013; Heijl et al., 2013). A better study design would use 
longitudinal data (Abe et al., 2016; Medeiros et al., 2015). Additionally, our study has the 
potential for response bias (49% response rate). However, given the adoption of a postal 
survey design and adherence to an ethical study protocol, a full response rate would be 
unlikely. As visual field data were unavailable for those who did not choose to participate, 
we were not able to consider the characteristics of non-responders. Nevertheless 49% is 
higher than response rates observed in studies using a similar design (Herndon et al., 
2006). We did not have information on race, educational level, and marital status and 
these factors can influence quality of life. In addition, there may have been a large gap 
in time between patient’s latest visual field data and when the completed NEI VFQ-25 
was returned. The main problem with the design of this study is absence of any clinical 
indictors on the eyes other than the visual fields. We did not, for example, have 
information on co-existing cataract or detailed treatment history. Additionally, for this 
unselected sample, we did not have measures of visual acuity. A further disadvantage of 
our analysis is that we did not use a Rasch model to analyse the results of the NEI VFQ‐
25, whereas studies similar to ours have done this (Abe et al., 2016; Medeiros et al., 2015; 
Peters et al., 2015). 
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 Our study opens up avenues for future research into the association between 
vision-related quality of life and clinical measures of vison loss. We found that the rate 
of decline in glaucoma patients’ vision-related quality of life begins to slow after BEMD 
is reduced to -5 dB. This slow decline in NEI VFQ-25 scores remains evident until BEMD 
is reduced to -15 dB, where rapid decline occurs. More research is needed in order to 
understand what factors can influence the rate at which patient vision-related quality of 
life declines. A well designed prospective study should consider vision-related quality of 
life in people at this moderate or middle stage of disease and consider how they might 
be adapting to their visual field loss. Moreover, we used only one measure of vision-
related quality of life, namely the NEI VFQ-25. Previous research has indicated that no 
single instrument covers all aspects of patients’ vision-related quality of life (Somner et 
al., 2012). As such, replication of this study assessing responses on an instrument specific 
to glaucoma would be an interesting addition to the literature. 
In conclusion, the relationship between vision-related quality of life and BEMD is 
a weak monotonic one. However, we provide some evidence to suggest this relationship 
may not be a linear one. The speed at which vision-related quality of life declines might 
better be described as gradually, where patients experience a period of adaption to their 
vision loss, and then suddenly, once patients’ functional abilities become significantly 
impaired. 
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Chapter Three - Measuring changes in vision-related quality of life in glaucoma 
It is important to measure the impact of a condition or therapeutic intervention on 
patients’ lives. In clinical studies, the measurement and assessment of vision-related 
quality of life is often performed through the use of PROMs. As described in section 1.6.1, 
PROMs allow for patients to report their health perceptions, and any changes in these 
perceptions can be monitored by healthcare professionals and data analysts. PROMs also 
offer a more robust means of collecting quality of life data than methods such as 
qualitative history taking as PROMs can be systematic and easily repeated. The use of 
patient-centred outcomes is not only important for research, but it can also improve 
clinical practice (Basch et al., 2016; Chen et al., 2013). Well-crafted PROMs can realign 
clinicians’ focus to something similar to the patient’s needs and wants, and offer the 
promise of better and more meaningful clinician-patient relationships (Nelson et al., 
2015). 
 In order to fully understand the impact of glaucoma on the patient’s life, PROMs 
must be able to measure the multidimensional aspects of the disease including everyday 
visual challenges, discomfort of treatment, inconvenience of ongoing care, and 
psychological elements.  The purpose of this chapter was to analyse glaucoma patients’ 
responses on a number of frequently used PROMs and to assess whether these measures 
are sensitive to changes in glaucomatous disease severity. The aim was to enhance our 
understanding of the impact of glaucoma in the early stages of the disease, which may 
in turn have implications for the design of clinical glaucoma trials in the future. 
The work presented in this chapter has been published in Ophthalmology; see list 
of supporting publications. The co-authors of this work are David Crabb (DC), David 
Garway-Heath (DGH), and Augusto Azuara-Blanco (AAB). Data were collected as part of 
the United Kingdom Glaucoma Treatment Study, a multi-centre, randomised, placebo-
controlled clinical trial. Access to the data were granted by DC and DGH. Data analysis 
was performed by LJ. The paper was written by LJ, and reviewed, edited, and approved 
by all authors. The work presented in this chapter has also been presented as a paper 
presentation at the Association for Research in Vision and Ophthalmology meeting 
(Seattle, WA, USA, 2016) and The United Kingdom and Éire Glaucoma Society annual 
meeting (Cheltenham, UK, 2016); see list of supporting publications. 
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3.1 Introduction 
Intraocular pressure (IOP) is currently the only modifiable risk factor for disease 
progression in glaucoma. All therapies approved for the treatment of glaucoma are 
licenced on their ability to reduce patients’ IOP. Yet, the foremost outcome when treating 
glaucoma is to maintain what is most important to the patient, vision-related quality of 
life (European Glaucoma Society, 2017). Randomised clinical trials have provided 
evidence for the visual field preserving benefit of reducing IOP (Holmin et al., 1988; AGIS 
Investigators, 2000; Kass et al.,2002; Heijl et al., 2002; Pajic et al., 2010; Krupin et al., 2011; 
Anderson et al., 1998; Migdal et al., 1994; Jay & Murray, 1988; Musch et al., 2009; Garway-
Heath et al., 2015). Recently, the United Kingdom Glaucoma Treatment Study (UKGTS) 
evidenced the effectiveness of an IOP lowering treatment in patients with glaucoma 
using visual field deterioration determined by standard automated perimetry as the 
primary outcome measure over a two-year follow-up period (Garway-Heath et al., 2015). 
Typically, outcome measures in clinical trials are selected on their sensitivity to 
clinically meaningful changes in disease severity. However, diagnostic test measurements 
taken in the clinic do not directly capture the impact of glaucoma on the patient’s life 
(Denniston et al., 2014). IOP is not a direct measure of glaucomatous optic neuropathy. 
Visual fields, however, indicate functional ability, and are therefore more closely 
associated with vision-related quality of life than IOP. PROMs are instruments derived 
from standardised, validated questionnaires that are used to measure perceived health 
status, functional status, or health-related quality of life. Asking a patient directly is an 
effective way to ascertain how someone feels about their condition and how it might be 
affecting their well-being (Deshpande et al., 2011). PROMs can also be readily translated 
into measures of cost-effectiveness. 
Use of PROMs in clinical research has increased in recent years (Black, 2013), and 
this is beginning to be mirrored in glaucoma research (Glen et al., 2011), where a 
catalogue of vision-specific PROMs are now available (Hamzah et al., 2011). PROMs are 
also becoming more frequently used in clinical trials (Vodicka et al., 2015), including in 
ophthalmology trials, (Chakravarthy et al., 2013; Varma et al., 2012; Mitchell et al., 2011; 
Sugar et al., 2014; Lois et al., 2011). Typically, PROMs are used to complement a more 
clinical primary outcome in trials. However, The United States Food and Drug 
Administration endorses the use of PROMs as primary endpoints in glaucoma trials (Food 
and Drug Administration, 2006), and this has been implemented in recent glaucoma trials 
(Azuara-Blanco et al., 2016; King et al., 2018; Vickerstaff et al., 2015). An important 
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attribute of a clinical trial outcome measure is to be sensitive enough to detect 
differences between a treatment and a control group. This is particularly true for 
glaucoma treatment trials because the disease process is slow and changes to vision can 
be challenging to measure. Moreover, disease progression in glaucoma is often 
unnoticeable to the patient in the early stages of disease (Crabb, 2016). A lack of 
sensitivity may necessitate prolonged trial duration which can add to the delay of drug 
development. For this reason, the sensitivity of PROMs when used as outcome measures 
in glaucoma trials should be scrutinised and this is the subject of our study. Specifically, 
we analyse PROM responses from patients in the UKGTS to test the hypothesis that these 
measures can determine differences between the groups randomised to treatment or 
placebo. 
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3.2 Methods 
In this study, we analyse the responses on PROMs of patients enrolled into the UKGTS, a 
multi-centre, randomised, triple-masked, placebo-controlled trial assessing visual 
function preservation in newly diagnosed open-angle glaucoma patients (trial 
registration number: ISRCTN96423140). Patients recruited from ten eye clinics 
throughout the United Kingdom were randomly allocated to receive an IOP reducing 
prostaglandin analogue Latanoprost (0.005%) or placebo eye drops. The UKGTS, and the 
subsequent analysis of anonymised data in this study, adhered to the tenets of the 
Declaration of Helsinki and was approved by local institutional review boards (ethics 
approval reference: 09/H0721/56). Study participants provided written informed consent. 
A total of 461 patients from 516 enrolled were analysed in the trial (Latanoprost 
N = 231, placebo N = 230). Patients in the UKGTS were scheduled to perform a series of 
11 visual field examinations during a 2-year observation period. Visual field progression 
was used as the primary endpoint in the trial. Progression analysis was performed in the 
Humphrey Field Analyser Guided Progression Analysis (GPA) software; a sensitive 
technique that considers changes at individual points (test locations) in the visual field. 
Progression was defined as at least three visual field locations worse than baseline at the 
5% levels in two consecutive reliable visual fields and at least three visual field locations 
worse than baseline at the 5% levels in the two subsequent consecutive reliable visual 
fields; the locations identified in the first and second pair were not required to be 
identical.  
Eligibility criteria for the UKGTS included presence of open angle glaucoma, 
defined as glaucomatous visual field defects in at least 1 eye with corresponding damage 
to the optic nerve head (cup-to-disc ratio of ≥0.7, focal narrowing of the neural rim, or 
both), with the presence of an open angle as determined by gonioscopy and the absence 
of retinal or neurological condition which may account for VF loss. The specific inclusion 
criteria for the study was as follows: newly detected, previously untreated open-angle 
glaucoma (including primary, normal-tension, and pseduoexfoliation) in either eye; age 
of older than 18 years; Snellen visual acuity of 20/40 or better; visual field MD of 2 post-
screening visual fields differing by no more than 3dB for an MD of better than -6.0dB, or 
by no more than 4dB for an MD worse than -6dB; and the ability to give informed consent 
and to attend for the duration of the study. Exclusion criteria were the following: 
moderate/advanced visual field loss (MD worse than -10dB in the better eye or worse 
than -16dB in the worse eye) or a threat to fixation in either eye (a paracentral point with 
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sensitivity of <10dB in both the upper and lower hemifields) in either eye; IOP of >35 
mmHg on 2 consecutive occasions in either eye or mean baseline IOP of 30 mmHg or 
more; inability to perform reliable visual field testing; poor quality structural imaging 
(assessed by Heidelberg Retina Tomography); cataract lens grading of more than N1, C2, 
or P1 according to Lens Opacities Classification System III grading; previous intraocular 
surgery (other than uncomplicated cataract extraction >1 year previous); and presence 
of diabetic retinopathy. (Garway-Heath et al., 2015; Garway-Heath et al., 2013). 
 
 
 
 
Figure 3.1: Kaplan-Meier failure estimates for visual field progression amongst patients in the UKGTS. 
Proportion of treatment patients found to be progressing at 6, 12, 18, and 24 months are represented by the 
blue line, proportion of placebo patients found to be progressing are represented by the red line. 
 
The results of the UKGTS highlighted the magnitude of the treatment effect in 
the trial. Difference in IOP between the treatment and placebo group after 24 months 
was relatively small (2·9 mm Hg), due to the fact that untreated pressures at study entry 
were quite low. IOP-reducing drugs produce much smaller pressure reductions in eyes 
that start with low pressures than in eyes in which pressure is high. Still, the risk of 
progression was substantially lower in the treated group than in the group receiving 
placebo drops (adjusted hazard ratio 0·44 [95% CI 0·28–0·69]) (Figure 3.1). This finding 
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shows that IOP reduction is highly effective, and that every mm of pressure counts when 
treating patients with early glaucomatous disease (Leske et al., 2007). 
PROMs were included as secondary outcome measures in UKGTS. PROMs were 
self-reported at patients’ baseline and final visit and were administered by a trial 
researcher. In the event of a patient meeting the primary trial endpoint, PROMs were 
completed upon the patients’ withdrawal from the trial. The PROMs used in UKGTS were 
as follows: 
European Quality of Life in 5 dimensions (EQ-5D) is a classification of general 
health status (EuroQoL, 1990). EQ-5D assesses five attributes: mobility, self-care, usual 
activity, pain/discomfort, and anxiety/depression. We used the three-level measure 
meaning each dimension has three possible outcomes: no problems, some problems, 
and severe problems. Patients with no problems across all five attributes will produce a 
five-digit health status code of 11111. Patients with severe problems will score 33333. 
Five-digit codes were translated into a single health state score using an existing scoring 
system which is generated from a UK population sample (EuroQoL, 1990). Included in the 
EQ-5D is a visual analogue scale (EQ-5D VAS) where patients are asked to score their 
own health between 0 and 100 (where 0 and 100 are worst and the best imaginable 
health). EQ-5D is the most commonly used general health PROM and is recommended 
in The National Institute for Health and Care Excellence guidelines for health economic 
analysis in the United Kingdom (Devlin & Brooks, 2017). Furthermore, following 
recommendations by the United States Public Health Service (Siegel et al., 1996), there 
now exists a large database of EQ-5D derived health statistics for the American 
population, too (Sullivan et al., 2005). 
Short Form-36 (SF-36) is another general health instrument featuring 36 items 
across eight domains relating to: physical functioning, role limitation due to physical 
problems, emotional problems, bodily pain, general health, social functioning, vitality, 
and mental health (Ware & Sherbourne, 1992). Responses are made on Likert-type scales 
and the 36 individual items can be translated to give a global score for general health 
(ranging 0-100) where lower scores reflect poorer self-reported health. Following the 
International Quality of Life Assessment Project translation of SF-36 into several 
languages (Aaronson et al., 1992), this PROM has become frequently used in cost-utility 
studies (Hall et al., 2011). 
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Glaucoma Quality of Life (GQL-15) instrument has 15-items and is disease 
specific being designed to assess the impact of glaucoma on vision-related quality of life 
(Nelson et al., 1999). The GQL-15 was derived from an initial 62-item pilot questionnaire; 
the 15-items were included in the final instrument due to their strong relationship with 
visual field loss in glaucoma patients (Nelson et al., 2003). GQL-15 has four subscales: 
central and near vision, peripheral vision, mobility, and glare/dark adaptation. Scoring is 
based on five-point Likert-type scales where a response of 5 denotes severe difficulty 
and 1 indicates no difficulty. The measurement scale ranges from 15 to 75 where higher 
scores represent poorer vision-related quality of life. The instrument has been used in 
well-designed cross-sectional studies assessing the impact of glaucoma on patients’ 
quality of life (van Gestel et al., 2010; Goldberg et al., 2009). 
GQL-15 has previously been subjected to Rasch analysis to produce the 9-item 
Glaucoma Activity Limitation (GAL-9) PROM (Khadka et al., 2011). This instrument 
consists of a subset of nine items from the original GQL-15 and is considered to better 
reflect the effects of glaucoma on visual function (Khadka et al., 2011). GAL-9 has good 
external validity as scores from the instrument have been shown to correlate well with 
visual acuity and visual field scores. Furthermore, the GAL-9 is quicker to complete than 
the GQL-15 because it has fewer items (Khadka et al., 2011). In addition to our analysis 
of GQL-15 responses, we repeat the analysis on the items included in the GAL-9 for 
patients in the UKGTS. 
For the data analysis, responses on the PROMs at baseline and exit were 
transposed into percentage scores. (The exit visit was at 24-months or, for progressing 
patients, at the visit when progression was confirmed). Differences between these scores 
were used to detect the degree of change in each PROM between first and last trial visit. 
For example, no change is indicated by zero and scores greater than 0% indicate 
worsening on PROMs, i.e. patients report more problems on exit from the trial than at 
baseline; negative values indicate improvement from baseline. Two-sample independent 
t-tests were used to determine whether there was a statistically significant difference in 
change on PROMs between the two trial groups (treatment and placebo). 
Additionally, we assessed whether statistically significant differences in PROM 
responses could be observed between patients who remained stable during the UKGTS 
and those who experienced the primary trial endpoint. We included this additional 
analysis as it was anticipated that the largest difference in score for health-related and 
vision-related quality of life would be observed between these two patient groups. 
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3.3 Results 
Complete baseline and exit PROM data were available for n=182 (79%) and n=168 (73%) 
of patients with follow-up data in the treatment and placebo arm of the trial, respectively. 
Average change in scores was similar for both the treatment and placebo groups across 
all the PROMs (Table 3.1). There were no statistically significant differences between the 
trial groups on PROMs relating to general health. Furthermore, there remained no 
statistically significant differences between the two groups on the glaucoma-specific 
PROMs. In addition, the distribution in the baseline to exit scores were strikingly similar 
between the treatment and placebo groups (Figure 3.2). 
 
 
PROM 
 
Group 
 
 
 
Treatment 
N = 182 
Placebo 
N = 168 
 
Mean Difference [CI] 
 
 
p-value 
  
EQ-5D 1.7 (15.4)% 1.7 (10.6)% 0.0% [-2.8 to 2.8%] 0.98 
EQ-5D VAS 2.1 (12.5)% 1.9 (12.0)% 0.2% [-2.8 to 2.4%]  0.88 
SF-36 4.8 (19.8)% 5.0 (22.5)% 0.2% [-4.2 to 4.6%] 0.94 
GQL-15 2.7 (7.7)% 3.2 (11.7)% 0.5% [-1.5 to 2.6%] 0.66 
GAL-9 3.0 (8.5)% 3.2 (12.8)% 0.2% [-2.1 to 2.5%] 0.87 
     
MD -0.23 (1.9) dB 0.14 (2.0) dB  0.07 
Change from baseline to exit is shown as a percentage (%). Percentages show the 
average amount of change on each PROM for treatment and placebo group. Positive 
percentages indicate worsening from baseline.  
 
Table 3.1: Means (standard deviation) of percentage (%) change scores for the two trial groups (treatment 
and placebo) on PROMs between baseline and trial exit in the UKGTS. Mean (standard deviation) change in 
worse-eye mean deviation between baseline and trial exit in the UKGTS. More negative MD indicates 
improved scores from baseline. 
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Figure 3.2: Boxplots on the left show change in scores between baseline and exit PROMs for patients in the 
placebo group (blue) and the treatment group (green) in the UKGTS. Positive scores (higher than 0) indicate 
worsening from baseline. Boxplots on the right show change in progressing/worse eye MD score between 
baseline and exit visual fields for placebo and treatment groups. (MD is a summary measure used to 
represent overall reduction in visual field sensitivity relative to healthy aged-matched observers. Lower MD 
values (more negative) are indicative of greater loss of vision). Boxplots give median, interquartile range, 5th 
and 95th percentiles (whiskers). Due to large variability in   responses, 95th percentile is capped at 40% change 
for SF-36 analysis (SF-36 placebo 95th percentile = 54.6%; SF-36 treatment 95th percentile = 42.2%). 
 
 PROM data were not available at the exit visit for a proportion of patients in the 
UKGTS. Further analysis of those with missing data indicates that these patients had a 
similar profile to those with complete data (Table 3.2). Specifically, as determined through 
two-sample t-tests, there were no statistically significant differences between these two 
groups on baseline better eye mean deviation (MD) (p = 0.12), worse eye MD (p = 0.90), 
better eye visual acuity (p = 0.44), worse eye visual acuity (p = 0.56), and age (p = 0.27). 
As a group, patients without exit PROMs reported slightly worse average general and 
vision-related quality of life at baseline compared to those with exit PROMs. However, 
the magnitude of these differences was small; it might reflect some patients without exit 
PROMs being more likely to be people who were unwell at the start of the trial. For 
example, 32 patients had less than 21-months follow-up in the trial because of ill health 
and seven patients died during follow-up (Garway-Heath et al., 2015). 
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UKGTS patients 
with PROMs 
N = 350 
 
UKGTS patients 
without PROMs 
N = 166 
  
p-value 
MD (dB)     
Better eye     
 Mean  -0.5 (1.2) -0.8 (1.8)  0.12 
 Median  -0.5 [-1.3, 0.4] -0.6 [-1.4, 0.3]   
Worse eye     
 Mean  -4.2 (3.3) -4.3 (3.6)  0.90 
 Median  -3.3 [-5.6, -2.0] -3.4 [-5.7, -1.7]   
Best-corrected 
VA 
    
Better eye     
 Mean 1.0 (0.21) 1.0 (0.24)  0.44 
 Median 1.0 [1.0, 1.2] 1.0 [1.0, 1.2]   
Worse eye     
 Mean 0.9 (0.24) 0.9 (0.25)  0.56 
 Median 1.0 [0.67, 1.0] 1.0 [0.67, 1.0]   
Age (years)     
 Mean 65.8 (9.9) 67.4 (11.9)  0.27 
Sex     
 Male 188 (53.7%) 85 (51.2%)   
 Female 162 (46.3%) 81 (48.8%) 
 
  
Baseline PROM   Mean  
difference [CI] 
 
 
Mean     
EQ-5D 5 (7.2) % 5 (6.5) % 0 [0 to 3%] 0.53 
EQ-5D VAS 81 (15.1) % 75 (18.7) % 6 [2 to 13%] 0.03 
SF-36 77 (17.2) % 70 (19.9) % 7 [3 to 14%] 0.002 
GQL-15 7 (8.9) % 11 (12.7) % 4 [1 to 10%] 0.003 
GAL-9 7 (9.9) % 11 (14.7) % 4 [1 to 10%] 0.01 
 
Data are n (%) or mean (standard deviation) or median [interquartile range]. 
 
 
Table 3.2: Comparison of baseline characteristics between patients in the UKGTS with PROM data (N=350) 
and those without PROM data at exit (N=166). 
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 We assessed differences between stable patients (N=272) and patients with 
glaucomatous progression (N=78) as determined by the primary visual field outcome. 
Median (interquartile range) duration between baseline and progression confirmation 
visit was 465 (278, 553) days, in comparison to the 2-year (730 days) scheduled follow-
up for patients remaining stable.  No statistically significant differences were found 
between average responses from stable and progressed patients on PROMs relating to 
general health (EQ-5D, EQ-5D VAS and SF-36). Average differences between stable and 
progressed patients were statistically significant when assessing responses on glaucoma-
specific PROMs (GQL-15 and GAL-9) (Table 3.3 and Figure 3.3). As a group, patients who 
had progressed on visual fields therefore reported a reduction in glaucoma-specific 
vision-related quality of life that was different to those who had remained stable on visual 
fields. Mean (95% CI) scores for the progression patients on the GAL-9 and GQL-15 was 
6.5 (2.8–9.2) % and 3.9 (3.2–9.8) % respectively.  
PROM 
Outcome  
Stable 
N = 272 
Progressed 
N = 78 
Mean Difference 
 [CI] 
 
p-value 
EQ-5D 1.5 (13.5)% 2.4 (12.5)% 0.9% [-2.5 to 4.3] 0.62 
EQ-5D VAS 1.5 (11.8)% 3.6 (13.5)% 2.1% [-1.0 to 5.2] 0.23 
SF-36 4.6 (20.3)% 6.0 (23.6)% 1.4% [-3.9 to 6.7] 0.65 
GQL-15 2.1 (7.9)% 6.0 (14.3)% 3.9% [1.5 to 6.3] 0.02* 
GAL-9 2.1 (9.1)% 6.5 (14.8)% 4.4% [1.7 to 7.1] 0.02* 
MD -0.22 (1.9) dB 0.55 (2.1) dB  0.003* 
Change from baseline to exit is shown as a percentage (%). Percentages show the 
average amount of change on each PROM for stable and progressed trial outcomes. 
Positive percentages indicate worsening from baseline. * = significant at 0.05 level 
 
Table 3.3: Means (standard deviation) of percentage (%) change scores for stable and progressed patients 
on PROMs between baseline and trial exit in the UKGTS. Mean (standard deviation) change in worse-eye 
mean deviation between baseline and trial exit in the UKGTS. More negative MD indicates improved scores 
from baseline. 
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Figure 3.3: Boxplots on the left show change in scores between baseline and exit PROMs for patients 
remaining stable (purple) and patients with visual field progression (red) in the UKGTS. Positive scores (higher 
than 0) indicate worsening from baseline. Boxplots on the right show change in progressing/worse eye MD 
score between baseline and exit visual fields for stable and progression groups. Boxplots give median, 
interquartile range, 5th and 95th percentiles (whiskers). Due to large variability in responses, 95th percentile is 
capped at 40% change for SF-36 analysis (SF-36 stable 95th percentile = 42.4%; SF-36 progression 95th 
percentile = 53.8%). 
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3.4 Discussion 
Results from this study show average changes in scores on general health-related PROMs 
(EQ-5D, EQ-5D VAS and SF-36) to be similar for patients receiving either Latanoprost or 
placebo eye drops in the UKGTS. Moreover, we did not find any evidence for differences 
between the two arms of the trial when analysing changes in PROMs specifically relating 
to vision and glaucoma (GQL-15 and GAL-9). Therefore, PROMs used in the UKGTS 
measured once at baseline and at 2-year follow-up (or final review, for those exiting early 
as a consequence of visual field progression) are not as sensitive as serial visual fields, 
taken over the same time course, in determining treatment differences in disease 
progression in a trial for glaucoma treatment.  
There were other interesting findings from our study. Statistically significant 
differences were observed in average responses between stable and progressed patients 
on glaucoma-specific PROMs, but this was not the case for general health-related 
PROMs. This suggests general health-related PROMs are insensitive to treatment-
induced changes in glaucoma progression, certainly in the population of patients 
represented in the UKGTS within the 24-month observation period. Another finding, not 
directly related to the aim of our study, concerns differences between GAL-9 and GQL-
15. When comparing stable and progressing patients, GAL-9 yielded a marginally larger 
average effect (4.4%) when compared to the GQL-15 (3.9%). As such, we provide 
supporting evidence that the GAL-9 may be a satisfactory alternative to the GQL-15 when 
assessing glaucoma-specific vision-related quality of life. The GAL-9 has the added 
benefit of having fewer items and is therefore less burdensome for the patient to 
complete. 
Our results have implications for trial design for glaucoma treatments. The UKGTS 
highlighted that a relatively short observation period could be implemented when 
adopting a sensitive change-from-baseline event criterion to identify visual field 
progression. This was made possible by frequent visual field testing and sensitive 
statistical methods where measurements that were repeatedly worse than baseline were 
flagged. Our results suggest that PROMs may not be sensitive enough to be used as 
outcome measures in glaucoma treatment trials, especially over a relatively short follow-
up.  Yet, it is important to note in the UKGTS, patients only completed PROMs at baseline 
and exit visits. The difference in mean deviation (a global measure, in the same sense as 
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a questionnaire score) of the visual fields taken at baseline and final review was also not 
sufficiently sensitive to identify differences between the treatment and placebo groups. 
Therefore, the explanation of the inability of the PROM scores to identify treatment 
differences is that either the PROM scores are insufficiently responsive to the small 
changes in disease observed over the short trial duration or that the scores are 
insufficiently precise, or both. Indeed, PROMs administered more frequently during the 
trial may have reduced the within person variability in responses and increase the 
likelihood of capturing significant changes. We are aware of at least two ongoing 
glaucoma trials that are doing this, albeit in different PROMS to the ones used in UKGTS 
(King et al., 2018; Vickerstaff et al., 2015). Still, the relatively small effects and large 
variability in our PROM data indicate that even repeat measures may not provide 
adequate trial power. It is encouraging that our chosen primary end point for the UKGTS, 
namely visual field progression, was sensitive enough to detect changes that are likely 
imperceptible to most patients in the early stage of the disease.  It is important to note 
that our findings are based on the results of the UKGTS, where treated patients were 
compared to a placebo group. It is reasonable to suggest that the largest expected 
difference in scores between two arms of a randomised clinical trial would be when a 
placebo group is used. The fact that no differences were found when comparing 
treatment to placebo group in this study suggests that PROMs are very unlikely to be 
able to distinguish between patient groups in a trial comparing efficacy of two different 
interventions for glaucoma treatment, such as that in recent glaucoma clinical trials 
(Azuara-Blanco et al., 2016; King et al., 2018; Vickerstaff et al., 2015). However, in some 
of these cases the focus is not on patients with early glaucoma (King et al., 2018), and so 
greater differences between trial arms may be observed as vision-related quality of life 
is likely to decline faster amongst patients with advanced glaucoma, as discussed in 
Chapter Two (Jones et al., 2017; See supporting publications). 
Longitudinal studies have revealed an association between visual field 
progression and changes in vision-related quality of life in glaucoma patients (Medeiros 
et al., 2015; Abe et al., 2016; Peters et al., 2015; Diniz-Filho et al., 2016). Yet, these studies 
have tended to use global or regional measures of visual field derived from binocular 
measures. We are unaware of any longitudinal studies reporting changes in quality of life 
measures that are associated with progression events detected at a visual field test 
location level using GPA software. Ultimately, it makes sense that trial endpoints are 
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aligned to relevant and meaningful outcomes for the patient, and we have highlighted 
that disease-specific instruments, like GAL-9 and GQL-15, can track visual field loss 
amongst glaucoma patients. Moreover, it remains important that all stakeholders are 
considered when deciding on outcome measures in clinical trials, and that includes the 
patients themselves (Dean et al., 2017). 
Other observations on our results are noteworthy. Average changes in PROMs, 
where they existed, were small and the variability in response between participants was 
large. For example, the average 6% decline on the GQL-15 in the N=78 patients who 
were progressing on visual fields is equivalent of a change from ‘no difficulty’ to ‘a little 
bit of difficulty’ on just four of the 15 items on the GQL-15. This small average change in 
vison-related quality of life suggests that patients experiencing the visual field endpoint 
do not perceive large changes in visual function, in this cohort with glaucoma mostly at 
its earliest stage. This is an interesting finding because it has been suggested that 
placebo-controlled clinical trials for glaucoma treatment can be harmful for those 
randomised to the placebo arm (Wegner, 2015). However, our findings certainly indicate 
that vision-related and health-related quality of life was similar between patients in the 
placebo group to those randomised to treatment over the course of the trial. In the case 
of the UKGTS, all patients were monitored closely over a short trial duration and the 
criterion for visual field deterioration was proven to be very sensitive. On average, 
patients progressing, based on visual fields, experience a small or unnoticeable reduction 
in vision-related quality of life. They certainly do not, on average, experience a change in 
general health as measured by the general-health PROMs considered in our study and 
this is particularly noteworthy. These findings support an argument for close monitoring 
being an alternative to medical treatment in the early stages of the disease, an 
observation made from the results of previous clinical trials (Heijl et al., 2002; Anderson 
et al., 1998). As no statistically significant differences in PROM scores were observed 
between the treatment and placebo group in UKGTS, our findings might have 
implications for how health-related and vision-related quality of life are assessed in 
clinical trials. More objective or ‘real-world’ assessments of visual disability are emerging, 
and these have potential for use as trial outcomes that are meaningful to the patient. 
One such measure, the Assessment of Function Related to Vision (AFREV), requires users 
to perform visual tasks such as findings objects, using everyday technologies, and 
reading under various illuminations (Altangerel et al., 2006). If used as an outcome 
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measure, tools such as the AFREV may yield more discernible differences between 
treatment groups in glaucoma clinical trials, but this remains speculation until tested. An 
added advantage of such objective measures is that, unlike PROMs, they are less reliant 
on the functional literacy of the patient. Offering definitive guidance on the use of PROMs 
or visual fields, or a combination of the two, as outcome measures for glaucoma trials is 
beyond the remit of this study. These issues are complicated because, for example, 
PROMs are derived from the individual, who has two eyes, and the visual field outcome 
is derived from just one eye (the first showing progression), and in the UKGTS just 11% 
(n = 10) of progressing patients had visual field progression in both eyes. PROM 
performance in glaucoma is likely driven by the least affected eye but this is dependent 
on the stage of glaucoma (Skalicky et al., 2016; Arora et al., 2013); in the UKGTS, almost 
50% of participants had glaucoma in only one eye. Furthermore, the visual field 
progression outcome occurred in one eye only in almost 90% of participants with 
identifiable progression (94 of 461 subjects) and in 73% of these, the progression was in 
the worse eye. Thus, the person-level PROM outcome would be expected to be less 
sensitive to glaucoma deterioration than eye-based measures of visual function. For 
example, standard automated perimetry will detect changes in sensitivity that may be 
unnoticed by the patient, whereas PROMs will likely be more responsive to central visual 
field loss. This does not mean that PROMs do not have a role in treatment trials; they 
may have a more important role in identifying adverse (or even beneficial) effects of 
interventions on the person that they have in identifying disease modifying effects. 
The study was not without limitations. In some cases, not all patients completed 
PROMs at baseline or exit from the trial and so no comparable data were available for 
analysis. Yet, patients with and without PROM data had similar demographic and visual 
function profiles. One key limitation comes from patients possibly being aware of the 
status of their glaucoma progression (stable or worsening) at the time of completing exit 
PROMs. This is certainly true for patients withdrawn early from the trial because visual 
field progression had occurred. If, for example, a patient was told they were exiting the 
trial because their clinically measured vision was getting worse, then that would likely 
influence self-report of quality of life. If this were the case, one might expect knowledge 
of glaucoma progression status to affect general health-related, as well as vision-related, 
quality of life, but there were no differences in the EQ-5D or SF36 between those who 
progressed and those who did not. As previously discussed, the design of the UKGTS 
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meant that patients completed PROMs at only two time points. This is obviously different 
to the frequent collection of visual field data (primary outcome).  Our results are also 
limited to apply to only a UK population of newly diagnosed patients, most of whom 
were at the earliest stage of the disease. We cannot say how PROMs may change over a 
period of 24-months in people with more advanced disease. Patient’s vision-related 
quality of life may decrease more quickly when visual field loss is already quite advanced 
(Jones et al., 2017). A further limitation of this study is the fact we did not compare 
differences in groups per PROM item, but rather we used global scores for PROMs 
overall. However, we did compare scores between the original GQL-15 and the Rasch 
analysed variation, the GAL-9, and found the latter to be more sensitive to glaucomatous 
disease progression, as seen by the greater average difference in PROM change score. 
This would suggest that the Rasch analysis of the GQL-15 had already identified items 
that were most sensitive and relevant to a glaucoma population. Yet, it remains true that 
specific items on PROMs used in the UKGTS may be better able to distinguish between 
patient groups. For example, complaints about lighting conditions are common for 
patients with glaucoma (Burr et al., 2007; Nelson et al., 1999). Specifically, having difficulty 
with glare and light adaption have been ranked as the most problematic symptom of 
glaucoma; more so than trouble with mobility, reading, and socialising (Nelson et al., 
1999). Furthermore, problems with glare and lighting are frequently reported in patients 
with even mild cases of glaucoma (Burr et al., 2007), and glaucoma suspects with 
impaired scotopic vision are more likely to have signs of early optic nerve injury 
(Glovinsky et al., 1992). These findings suggest that difficulty with light adaption may be 
one of the earliest symptoms presented in patients with glaucoma, thus PROM items 
relating to dark and light adaptation may be particularly sensitive at detecting changes 
between patient groups. This idea is being explored further in a large-scale project to 
assess the impact of lighting conditions in patients with glaucoma, and the author of this 
thesis is currently involved in a systematic review of the literature in this area (Available 
Online: www.crd.york.ac.uk/prospero/. Review ID CRD42018118953). 
In conclusion, patients randomised to treatment or placebo in the UKGTS 
returned similar responses to PROMs at baseline and final visits of the trial. It is accepted 
that no single PROM covers all aspects of patients’ vision-related quality of life (Somner 
et al., 2012), and our findings at least emphasise the importance of appropriate PROM 
selection when designing and implementing clinical trials. Even if PROMs cannot capture 
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the disease modification effect of an intervention, that certainly does not mean that they 
are not useful if they can capture other consequences of an intervention including, for 
example, side effects or inconvenience of treatment regimens. In the UKGTS differences 
in PROM responses only emerged when comparing stable and progressed patients on 
instruments that were specific to glaucoma. As such, we suggest PROMs alone, 
administered at the start and end of a 24-month trial assessing disease progression, may 
not be sensitive enough to be used as the primary endpoints in glaucoma clinical trials 
assessing disease progression.  
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Chapter Four - Monitoring glaucoma patients in the hospital eye service 
Once diagnosed, patients with glaucoma require lifelong monitoring, often within the 
hospital eye services. Repeated clinic visits can pose as a significant burden for patients 
living with chronic disease, where long waiting times and financial constraints can impact 
on glaucoma patient’s quality of life (Kotecha et al., 2015a; Kong et al., 2014). Glaucoma 
patients have described significant concerns about aspects of their care, including 
delayed appointments, long waits to see a professional at each appointment, and rushed 
consultations. A report from the RNIB entitled ‘Saving money, losing sight’ (RNIB, 2013) 
highlighted the key aspects of glaucoma monitoring patients were concerned about: 
 
“The eye hospital clinics are total chaos! The appointment time bears no relationship to when 
you will be seen. I find it hard to sit for hours not knowing what is happening” 
“I knew delays would lead to permanent damage that could never be reversed – I started to 
think I would never gain access to what I needed to save my sight before I lost it forever” 
“When the specialist says he wants to see you in three months, you should see him in that 
timeframe, instead of having to wait seven months during which time your condition has 
worsened” 
 
Virtual glaucoma clinics may offer one solution for the concerns about hospital 
capacity. As described in section 1.4.7, a virtual glaucoma service may improve in-patient 
capacity and reduce hospital delays, subsequently reducing the burden of monitoring for 
the patient. However, it is important to consider whether a virtual glaucoma service is a 
viable means of monitoring patients, and this is the focus of this chapter. Although 
quality of life is not directly measured in this study, the findings may have significant 
implications for the way in which glaucoma patients are monitored in the hospital eye 
service, and consequently affecting patient quality of life. 
The work presented in this chapter has formed a paper published in British 
Journal of Ophthalmology (Jones et al., 2017); see list of supporting publications. The co-
authors of this work are David Crabb (DC), Susan Bryan (SB), Marco Miranda (MM), and 
Aachal Kotecha (AK). Access to the data was approved by AK, the Caldicott Guardian, and 
Information Governance Lead at Moorfields Eye Hospital NHS Foundation Trust. Help 
with data extraction came from MM. Help with data analysis and plotting of the 
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‘Hedgehog’ plots came from SB. Data extraction and analysis were performed by Lee 
Jones (LJ). The paper was written by LJ, and reviewed, edited, and approved by all authors. 
The work presented in this chapter has also been presented as a poster presentation at 
the British Congress of Optometry and Vision Science (Plymouth, UK, 2017); see list of 
supporting publications. 
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4.1 Introduction 
The UK National Health Service (NHS) is facing unprecedented challenges. Although 
overall life expectancy is increasing, with it comes a greater prevalence of disease in the 
population (Murray et al., 2015), and chronic disease management remains a significant 
burden on the NHS (Lewis & Dixon, 2004). There is a need for the NHS to redesign its 
services to make a more efficient healthcare service provider.  
A drive exists for the NHS to make more use of information technology (IT) 
(Department of Health, 2016). One such example is the development of virtual clinics, 
which remove the face-to-face doctor-patient consultation.  Within the hospital eye 
service (HES), virtual clinics have not only been found to provide valuable additional out-
patient capacity, but can also streamline referral rates, reduce costs, and improve the 
patients’ health care experience (Kotecha et al., 2015a; Trikha et al., 2012; Ross et al., 2016; 
Vardy et al., 2014). Improvements in disease detection by primary eye care service 
providers have meant that the HES has become one of the busiest health care providers 
in the UK (Vernon et al., 2011; Edgar et al., 2010; Khan et al., 2012; de Silva et al., 2013). 
As a result, the introduction of new methods to assist with the monitoring of patients 
with chronic ocular disease in the HES is a high priority.  
Virtual clinics offer a viable means of monitoring glaucoma patients (Trikha et al., 
2012; Rathod et al., 2008; Wright & Diamond, 2014; Clarke et al., 2017). To date, most 
studies have focused on the accuracy of disease staging, as well as patient satisfaction, 
cost reduction, and appointment durations (Kotecha et al., 2015a; Clarke et al., 2017; 
Kotecha et al., 2015b. An important safety aspect of virtual clinics is whether disease 
progression can be identified and acted on effectively. By doing so, scrutiny can be 
placed on the extent to which virtual clinic patients differ from patients in consultant-led 
appointments when performing the same tests. This type of analysis can be conducted 
through an audit-style assessment using large scale data.  
 Following the development and expansion of the Internet, as well as the advent 
of new and innovative technologies, the use of large scale data, or “big data”, has 
increased dramatically in recent years (Raghupathi & Raghupathi, 2014). Put simply, large 
databases from routine services can be used to compare individual or population results 
of patients attending a single hospital, practice, or clinic. This method has been used 
recently in the field of ophthalmology (Boodhna & Crabb, 2015; Sparrow et al., 2011). 
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A virtual clinic must be effective at identifying patients who have become 
unstable and are in need of closer observation. One method to assess this aspect of 
virtual clinics is to use large scale data collected from consultant-led appointments as 
benchmarks for patient’s measurement results. This is the idea explored in this current 
work. 
In this study, we examine the effectiveness of a virtual glaucoma monitoring 
service (GMS) at identifying unstable patients requiring closer observation. In addition, 
we assess whether “big data” analysis can be used to identify patients achieving visual 
field test scores outside of the expected range. 
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4.2 Methods 
Following authorisation from the Caldicott Guardian and Information Governance Lead 
at Moorfields Eye Hospital NHS Foundation Trust (MEH), anonymised visual field results 
from the Humphrey Field Analyser (HFA; Carl-Zeiss Meditec, Dublin, CA, USA) of patients 
attending the glaucoma monitoring service (GMS) were analysed. The GMS, and criteria 
for patient inclusion into the service, is described in a previous publication from our 
group (Kotecha et al., 2015a). In brief, clinical examinations of ‘early’ and ‘moderate’ 
disease stage glaucoma patients are carried out by trained ophthalmic technicians and 
data are reviewed by two consultants and a senior glaucoma specialist optometrist on a 
different day for clinical management decisions (Kotecha et al., 2015a). 
Inclusion criteria required patients to have at least two visits to the GMS no less 
than 4 months apart. The first 250 patients who entered the GMS since its start in 2014 
who fulfilled this criterion were analysed. This sample represents approximately 15% of 
patients attending the GMS at the time of data collection.  
Visual field data were manually downloaded from two (of two) HFAs located in 
the virtual clinic (performed by LJ). This process involved searching both machines for all 
clinic visits for each of the 250 patients included in the study. Once measurements were 
located for both eyes on all visits to the virtual clinic, the Portable Document Format 
(PDF) outputs were downloaded and individual data were inputted into a spreadsheet. 
These data were restricted to patient’s age, test date, test eye, test reliability, and mean 
deviation (MD). The latter is conventionally used in clinics; it is a summary measure of the 
overall reduction in visual field sensitivity relative to a group of healthy age-matched 
observers, with more negative values indicating a worse visual field. We used patients’ 
worse eye (based on MD) at their first GMS visit as our study eye. In addition to the 
manual data extraction, the same PDF outputs underwent the optical character 
recognition function using a purpose-written program authored in MatLab 2016b 
(Mathworks Inc.). Optical character recognition is a technique of translating handwritten, 
typewritten or printed text characters to a machine-encoded text. It is widely used as a 
form of data entry from printed paper data records, such as clinical computerised 
documents. The process involves an image being captured by digital camera and is 
converted into a suitable form required by the machine. Thus, it allows for digital texts 
to be electronically edited, searched, stored more compactly, displayed on-line and used 
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in machine processes (Chaudhuri et al., 2017). Equivalence was assessed between the 
manually collated visual field spreadsheet and the computerised data download. In the 
few instances where discrepancies occurred, the original raw data was revisited and the 
correct value was input into the spreadsheet.  
Data Analysis: We used the difference in MD between GMS patients’ baseline and second 
appointment as a surrogate of visual field stability. Large differences would suggest a 
change in the visual field, or poor repeatability.  
Limits were defined for change in MD from a database of 473,252 visual field 
records (the reference database). These data are described elsewhere (Boodhna et al., 
2015), and were pooled from 88,954 patients from four centres in the United Kingdom: 
Moorfields Eye Hospital NHS Foundation Trust, London; Cheltenham General Hospital 
Gloucestershire Eye Unit; Queen Alexandra Hospital, Portsmouth; and the Calderdale and 
Huddersfield NHS Foundation Trust. Only patients tested using the 24-2 testing 
algorithm were included, resulting in a total of 83,794 patients. 
Patients attending the GMS are all experienced in perimetry, but this may not 
necessarily be true for patients within the reference database. Thus, we excluded the first 
ever visual field test for patients within the reference database to allow for perimetric 
'learning'. Furthermore, eliminating the first visual field in a patient's series would also 
exclude patients from the reference database who had a single, exploratory visual field, 
thereby increasing the confidence that patients remaining in the reference database who 
had at least 2 subsequent visual fields were being monitored for glaucoma. In this 
database, 41,048 patients (49%) were excluded based on this criterion. In addition, we 
restricted the age (minimum age of 20 years) for the reference database to ensure that 
these patients were age-related to patients seen in the GMS. Duration between 
appointments in the reference database was restricted to between 4 and 24 months to 
ensure similar time intervals for follow up between the two groups. After applying these 
criteria, 22,124 patients remained in the reference database. We then grouped the 
average MDs by visual field defect severity using bins of 1dB width. We did this because 
visual field measurement repeatability is strongly associated with visual field severity 
(Russell et al., 2013). The 5th, 25th, 75th and 95th percentile of the distribution of difference 
were then derived and plotted. Points were connected using a locally weighted 
smoothing operator (LOESS) to create a colour coded chart for the 50% and 90% limits 
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of change for MD in the reference database (See figure 4.1).  We would, for example, 
expect 10% of GMS patients to have repeat MD differences outside of the latter limits. 
By using this method, GMS patients who had visual field results that were markedly 
different to those in the reference database (i.e. outside the 90% normal limit) could be 
identified. 
For the second part of the analysis, we included a subset of the GMS patients who 
had attended three or more appointments (N=158). GMS patients with three visual fields 
were compared to patients in the reference database with three visual fields; this was 
repeated for patients with four and five visual fields. Where two visual fields were 
conducted within 4 months, the patients’ next measurement in their visual field series 
within our inclusion criteria was used. Simple linear regression was used to calculate the 
rate of visual field progression (MD dB loss per year). Regression lines for the reference 
database were plotted using a novel data visualisation tool, the Hedgehog Plot. This tool 
allows us to visualise the progression rates for all patients simultaneously. The reference 
database was used to determine the 90% limits by computing the 5th and 95th percentiles 
of the estimated slopes. The regression lines for the GMS patients were then 
superimposed onto the Hedgehog plot and eyes which were found to be outside of the 
calculated limits were flagged.  
The clinical management decisions for all 250 GMS patients at the time of their most 
recent field were also collected. All statistical analysis was done in R (www.R-
project.org). 
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Figure 4.1: Distribution of expected limits for size of difference in MD (dB) index between two appointments 
in the reference database (N = 22,124) based on the patient’s average MD. Areas at the upper and lower 
most part of the plot (red) show results outside of 90% normal limit. The lower most part of the plot indicates 
worsening visual field results. 
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4.3 Results 
Median (interquartile range; IQR) age of GMS patients at first visit was 65 (54, 72) years. 
Median (IQR) MD for GMS patients’ worse eye at baseline was -1.5 (-3.1, -0.3) dB. 
Median (IQR) number of months between the first and second GMS clinic 
appointments was 12 (10, 12) ranging from 4 months to 21 months. Average MD of the 
first and second appointments of the 250 GMS patients ranged between +1.6 dB and -
18.9 dB (median -1.4 (-3.0, -0.4) dB). Median (IQR) age of patients from the reference 
database was 67 (57, 76) years. 
Of the 250 GMS patients, 12 (4.8%; 95% confidence interval [CI] 2.5 to 8.2%)) 
recorded values outside the 90% limits. This proportion was less than the expected value 
of 10% and was statistically significant (p = 0.003). (A post-hoc power calculation 
confirms our study to have had an adequate sample size. A total of 4.8% outside the 90% 
limit returns a power (beta) value of 0.86 when alpha is set at 0.05 and N = 250; Minitab 
17 Statistical Software (2010); www.minitab.com). 
Figure 4.2 shows the results of the GMS patients (points) compared to the 
reference database. We split the GMS patients into three equally sized groups. Plot A 
ranges from -18.9 dB to ≤ -2.4 dB (83 GMS patients), plot B ranges from > -2.4 dB to ≤-
0.8 dB (84 GMS patients), and plot C includes patients > -0.8 dB (83 GMS patients). 
 
 
Figure 4.2: Virtual GMS patient (points) data compared against the reference database. Our total sample 
(N=250) is divided into 3 groups based on average MD. Plot A ranges from -18.9 dB to ≤ -2.4 dB (83 virtual 
GMS patients), plot B ranges from >-2.4 dB to ≤-0.8 dB (84 virtual GMS patients), and plot C includes 
patients > -0.8 dB (83 virtual GMS patients). 
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Figure 4.3 shows the rate of visual field progression for patients in the reference 
database. Each line represents an eye, with the length of the line indicating the length of 
follow-up. The location of the line is aligned to the patient’s age (x-axis) and severity of 
initial loss (y-axis); steeply declining lines indicate rapidly progressing eyes. After applying 
our inclusion criteria, 18,414 reference database patients were included. 
 
Figure 4.3: Hedgehog plot showing the rate of visual field progression in the reference database (N=18,414). 
Three patients have been highlighted. For each patient, a point represents a score on the visual field test and 
patients’ age at time of test. A regression line is fitted for each patient using all of the points in their series. 
Steeply declining lines indicate faster visual field progression. The blue shaded area denotes likely visual 
impairment. In this example, patient 1 has the most visual field tests in their series and shows a faster rate of 
progression than patient 2 or 3. 
 
 In Figure 4.4, GMS patients progressing (red lines) and improving (green lines) 
faster than the 90% limit in the reference database with the same number of visual fields 
are highlighted. Three (1.9%; 95% CI 0.4 to 5.4 %) patients are flagged as having visual 
field changes outside of expected limits.  
Table 4.1 shows the diagnoses of the 14 patients identified by both analyses as 
having visual field MD changes outside the 90% limits of the reference database. Twelve 
patients were identified in the first analysis, three in the second analysis, however one 
patient was identified in both analyses, and hence a total of 14 patients were identified 
across both analyses. Nine patients performed worse than patients in the reference 
database, although five of these had a positive MD at their baseline GMS visit. Of the 
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remainder, one patient was judged to be progressing by the GMS reviewer, one patient 
had a retinal arterial occlusion unrelated to their glaucoma, one patient was exited from 
the GMS due to suspected unreliable visual field performance, and one was deemed 
stable by the GMS reviewer and kept in the clinic. 
 
Figure 4.4: Of the 250 virtual GMS patients, 158 (63.2%) had 3 or more visual fields in their series. These 
patients are superimposed on the reference dataset Hedgehog Plot. Grey lines show rates of progression for 
patients in the reference database.  Darker lines show virtual GMS patients. Red lines highlight the virtual 
GMS patients outside the 90% limits for progression. The green line highlights the virtual GMS patient 
outside the 90% limits for ‘improvement’.  
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Key. MD = mean deviation, GMS = glaucoma monitoring service, OHT = ocular 
hypertension, POAG = primary open angle glaucoma. 
 
Table 4.1: Outcomes of GMS patients identified as falling outside of the 90% limits in the reference database. 
* = shown to be significantly progressing with both analyses 1 & 2. 
 
Age 
(years) 
Diagnosis MD at first GMS 
visit (dB) 
Progressing (P) 
or ‘improving’ 
(I) 
GMS outcome recorded in notes 
49 
 
OHT +1.03 P Remains in GMS; 12-month review 
52 
 
OHT -22.59 I Exited GMS in January 2015; noted to be poor 
visual field performer; moved to consultant 
clinic for further follow up. 
63 
 
OHT -2.60 I Remains in GMS; 9-month review 
65 
 
OHT -2.08 I Remains in GMS; 12-month review 
67 
 
OHT +1.45 P Remains in GMS; 6-month review 
71 
 
OHT +1.56 P Remains in GMS; 12-month review 
75 
 
OHT +0.03 P Remains in GMS; 12-month review 
77 OHT -2.02 P Remains in GMS; 18-month review 
78 
 
OHT -3.24 I Remains in GMS; 12-month review 
42 
 
Glaucoma 
suspect 
 
+1.55 P Remains in GMS; 12-month review 
55 Glaucoma 
suspect 
-4.17 P Exited GMS April 2016; discharged from 
service- no evidence of glaucoma, poor visual 
field performer. 
77 * 
 
Glaucoma 
suspect 
-2.16 P Retinal arterial occlusion; detected in March 
2016 (i.e. pre-glaucoma service visit); 
glaucoma stable. 
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Glaucoma 
suspect 
-13.78 I Exited GMS June 2016; no evidence of 
glaucoma, poor visual field performer; moved 
to consultant clinic to assess suitability for 
discharge from glaucoma service. 
82 POAG -7.97 P Exited GMS April 2016 as evidence of 
progression. Review in consultant clinic. 
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4.4 Discussion 
Our study exploited a “big data” approach to investigate whether patients in a GMS score 
similarly on a measure of vision loss (i.e. visual field MD) to patients who attend 
consultant-led appointments (reference database). Our results show the difference in MD 
values between two hospital appointments for patients attending the GMS is similar to 
those in the reference database. 
 Using “big data” we created ranges of expected change in MD over a similar 
follow up interval, using patients with a similar profile to those attending the GMS. Our 
findings also showed that 12 patients in the GMS scored outside the expected range on 
the visual field test. The proportion of GMS patients outside the expected range (4.8%) 
is smaller than the 10% (25 patients) we allowed for. Similarly, when compared to the 
reference database, there were fewer GMS patients with unusually fast progression. The 
results of our study indicate that the number of patients in a GMS performing better or 
worse than expected on the visual field test is smaller than anticipated.  
 The results of our study are relevant to current clinical practice with regard to 
monitoring patients with glaucoma. Our findings suggest that patients attending a GMS 
are no ‘worse-off’ than those attending the standard-care appointments. Specifically, 
when using visual field data from a large reference database as benchmarks for expected 
changes in MD score, GMS patients’ visual field test results tended to be as expected. In 
the few cases where GMS patients’ MD scores were outside the expected results, further 
analysis on these patients was carried out. It was found that 5 patients scoring outside 
the expected results had been highlighted as ‘improving’. Of the 7 patients showing a 
worse performance compared to the reference database, 3 had been picked up by the 
GMS reviewer, with the remainder being deemed stable. It should be noted that those 
deemed clinically stable had a diagnosis of either ocular hypertension or suspected 
glaucoma with no significant visual field defect.  
 A strength of our study is the number of patients we included in our analysis. 
Access to a wealth of visual field entries in the reference database, even after applying 
sensible selection criteria, meant that we closely matched patients in the GMS to patients 
attending standard, consultant-led appointments. The total number of patients in the 
reference database for the first part of our analysis was 22,124 and 18,414 for the second 
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part. These large numbers allowed limits for variability to be stratified by disease severity 
(Russell et al., 2013; Chauhan et al., 1993; Henson et al., 2000) 
It should be noted that the number of patients in the reference database used to 
create our expected limits is not equal across all average MD bins on the x-axis of our 
plots. For example, the number of reference database patients creating the -15 dB 
average MD limit was 257, whereas the number of patients creating the -5 dB average 
MD limit was 1,350. However, we wished to include as much data as possible and so, 
given that there were simply more patients with average MD of -5 dB than -15 dB, this 
disparity is to be expected. Additionally, the -15 dB limits were where the fewest 
reference database patients were included (N=257), but this number of patients remains 
substantial. A further point to consider is that in Figure 4.4 it appears older patients have 
less stable visual fields in the GMS. This could be due to these patients presenting at a 
later stage in the disease, precipitating more visual field variability, or they have had the 
disease for a longer period of time, or they are worse test takers. 
A limitation to our study is the inclusion criteria we used to construct the 
reference data percentiles (Figure 4.1). We match GMS patients to reference database 
patients using baseline MD, age, and interval between clinic visits. We did not have access 
to reference database patients’ diagnoses. GMS patients are a highly selected sub-group 
of glaucoma patients attending the Moorfields Eye Hospital glaucoma outpatient service; 
some reference database patients would not be suitable for virtual monitoring. For 
example, glaucoma patients with a coexisting ocular comorbidity would not be suitable 
for GMS but may be present in the reference database and this represents a possible 
confounder. Furthermore, we anticipated that patients in the GMS would be experienced 
in performing the visual field test. However, some GMS patients appeared to show 
improvement in their MD scores; these patients may be unreliable at performing the 
visual field test or are continuing to have perimetric learning effects despite being 
experienced test-takers. We did not have data for variables such as intraocular pressure, 
or optic nerve assessment which may influence progression. This is a key limitation. 
Further analysis adjusting for these factors would be a valuable addition to the literature. 
Patients in the “big data” (reference) group are simply defined as having measurable 
glaucoma-like visual field loss who are attending glaucoma clinics. Therefore, for 
example, we cannot rule out some patients having optic neuropathies that produce 
glaucoma-like visual field deficits, but the number would be insignificant given the sheer 
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number of records in the reference database. Moreover, for example, patients with 
sudden onset retinal vein occlusions or unstable aggressive glaucoma may skew the 
expected parameter limits in the reference database. However, as the reference database 
is comprised of patients attending glaucoma clinics, the number of those with visual field 
loss due to non-glaucomatous comorbidities is likely to be smaller than that reported in 
general population prevalence estimates (Mitchell et al., 1996). But these examples do 
highlight some limitations of the "big data" approach. A final limitation surrounds the 
method used to assess change between visual fields. Here we have used a visual field 
index (MD) and alternative methods using all the points in the visual field might offer 
more sensitivity to change (Bryan et al., 2013). 
The average number of appointments for GMS patients in our study was three. 
Further analysis where patients attending a GMS are followed longitudinally may provide 
more information regarding the suitability of virtual monitoring. Given that GMS are a 
relatively new addition to the HES, this idea should be revisited in future research.  
To our knowledge, this is the first study that utilised “big data” to evaluate 
outcomes of patients in a GMS. The utility of pooling large databases together to identify 
trends and also predict future risks to health is recognised elsewhere (Bradley, 2013). In 
the presented study, we have utilised “big data” to assess whether a new model of service 
delivery results in equivalent outcomes to that of the standard out-patient model, and 
for the metric we used (i.e. MD), we found that it did. The digital nature of visual field test 
results lends itself to “big data” analysis. Still, the visual field result is but one measure of 
glaucoma status. However, we feel that this study has shown the potential of using “big 
data” in the ophthalmology setting to confirm the equivalence of care between a new 
and standard model of service delivery.  
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Chapter Five - The experience of surgical intervention for advanced glaucoma 
Researchers have recognised the unique impact ophthalmic surgery can have on 
patients’ psychological wellbeing (Nijkamp et al., 2004; Marback et al., 2007). Fear of 
blindness following trabeculectomy glaucoma surgery have been reported amongst 
patients with advanced-stage of the disease (Cross et al., 2009). Moreover, patients with 
early glaucoma and good binocular vision have also cited vision loss as a result of surgery 
as a primary concern (Janz et al., 2001). Advanced glaucoma patients undergoing surgery 
on the better or ‘only’ eye represent a unique cohort of patients in the hospital eye service 
who may have experienced unprecedented challenges in their treatment journey, and 
can provide detailed insight into the experiences of advanced glaucoma and surgical 
intervention.  
There are currently no standardised definitions for what constitutes an ‘only eye’, 
but when considered from both a patient and surgical perspective, one could use 
characteristics which focus on the impact of loss of the eye. The practical working-
definition used for this study was: 
“An eye was considered an ‘only eye’ when significant loss of vision in this eye 
would be deemed life-changing with profound impact on the quality of life by 
both patient.” 
The purpose of this study was to learn about the surgical experiences of patients 
undergoing only-eye surgery for glaucoma. In addition, as these surgeries can be 
considered as high-stakes, as negative outcomes may result in visual disability for the 
patient, experiences of surgeons performing only-eye glaucoma surgery were also 
explored. Both patients and surgeons were asked to recall their experiences of these 
high-stakes procedures using semi-structured interviews. For the purpose of structuring 
this chapter, the review of literature, data interpretation, reporting of findings, and 
discussion of results are divided into two sections, the first relating to surgeon 
perspectives (Section 5.1 to 5.4), and the second relating to patient perspectives (Section 
5.5 to 5.8). 
 The co-authors of this work are Deanna Taylor (DT), David Crabb (DC), Freda Sii 
(FS), Imran Masood (IM), and Peter Shah (PS). Ethical approval was gained by Lee Jones 
(LJ), help with recruitment came from FS, IM, and PS. Help with data analysis came from 
DT, FS, IM, and PS. The results were interpreted by LJ and reviewed, edited, and approved 
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by all authors. The work presented in this chapter has also been presented as a poster 
presentation at the Association for Research in Vision and Ophthalmology meeting 
(Honolulu, HA, USA, 2018); see list of supporting publications.  
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5.1 Introduction – Surgeon experience 
All ophthalmologists will have patients under their care who have effectively only one 
seeing-eye.  The fellow eye may have suffered severe loss of vision from various causes 
including trauma, surgical complications, and advanced disease (e.g. glaucoma), or may 
have had long-standing poor visual function from dense amblyopia. These patients who 
effectively have just one seeing-eye (‘only-eye’) are always a concern for their 
ophthalmologists, but particularly when the better seeing-eye develops problems that 
need surgical intervention, such as glaucomatous progression. However, in moving into 
a surgical zone, both patient and surgeon are faced with the hard fact that surgical 
complications in the intra -  and post-operative period in an only eye may result in 
sudden, total, and permanent loss of vision, with life-changing consequences. It is for this 
reason that we believe that only-eye surgery is appropriately considered as ‘high-stakes’ 
surgery. 
Complications encountered during or after surgery pose a real threat to patients’ 
visual function, and loss of vision in the ‘better’ eye can have a significant impact on 
quality of life (Jones et al., 2017 (See chapter 2); Peters et al., 2015; Glen & Crabb, 2015; 
Kotecha et al., 2012; Ramulu et al., 2014). This is particularly true for only-eye patients 
where the ‘worse’ eye is significantly sight impaired. Incisional ocular surgery, such as 
trabeculectomy, generally carries a low complication incidence rate (Kirwan et al., 2013). 
Yet, potentially sight-threatening complications, such as postoperative infection and 
haemorrhage, cannot always be discounted, and unfortunately do occur following these 
routine procedures (Edmunds et al., 2002). Regrettably, such incidents have been 
reported in only-eye surgery (Eradurman et al., 2006), with a possible outcome of total 
extinction of the patients’ residual vision. Thus, the decision to operate on a patient’s 
only-eye is clearly not one that should be taken lightly. 
Researchers have recognised the unique impact ophthalmic surgery can have on 
patients’ psychological wellbeing (Cross et al., 2009; Janz et al., 2001). Indeed, only-eye 
patients have been found to be more fearful before surgery than binocular patients, 
citing blindness and surgical complications as their primary concerns (Marback et al 
2012). Research has highlighted the increased levels of perceived stress amongst surgical 
staff when operating on complex or high-risk patients (Anton et al., 2015), and only-eye 
surgery often fits both these criteria. Therefore, we believe research into how ophthalmic 
surgeons approach only-eye surgery, such as strategies for risk reduction, and 
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management of performance anxieties inherent in this type of surgery, is warranted. The 
only-eye surgery-performing cohort of ophthalmologists in the hospital eye service can 
provide valuable insight into the realities of performing these high-stakes procedures, 
the challenges to overcome, potential strategies for effective coping, and service delivery 
issues. The purpose of this study was to explore ophthalmic surgeons’ experiences of 
performing only-eye surgery with the aim to improve the journey for both the patient 
and the surgeon, and to minimise the risk to both. 
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5.2 Methods 
In medicine stories of illness and healthcare experience are well recognised as a rich 
source of information.  In qualitative research, stories told during interviews, help to set 
a patient-centred agenda.  They may challenge what is already known, and can generate 
new insights and understanding. Thus, qualitative data can be an important educational 
resource to help in dealing with patients’ problems holistically, and to enhance 
continuing professional development of health care staff. This type of research in 
ophthalmology has investigated patients’ experience of visual impairment, and aspects 
of the patient journey (Cammack et al., 2016; Cross et al., 2009).  This project is the first 
to focus on people who have vision in only one eye, and who have faced the challenge 
of having surgery on that eye.   
This project uses extended semi-structured interviews, to learn more about what 
the experience of only-eye surgery is like.  In particular, we want to find out how 
glaucoma patients and ophthalmic surgeons make sense of the only-eye experience for 
themselves. Qualitative methods, such as interviews, are believed to provide a ‘deeper’ 
understanding of social phenomena than would be obtained from purely quantitative 
methods, such as questionnaires (Silverman, 2000). Interviews are, therefore, most 
appropriate where little is already known about the study phenomenon, such as in the 
field of only eye surgery. They are also particularly appropriate for exploring sensitive 
topics the likes of surgical experience, as participants may not want to talk about such 
issues in a group environment such as focus groups. 
Semi-structured interviews consist of several key questions that help to define 
the areas to be explored, but also allows the interviewer or interviewee to diverge in 
order to pursue an idea or response in more detail (Britten, 2006). This interview format 
is frequently used in healthcare-related research, as it provides participants with some 
guidance on what to talk about, which many find helpful. The flexibility of this approach, 
particularly compared to structured interviews, also allows for the discovery or 
elaboration of information that is important to participants but may not have previously 
been thought of as pertinent by the research team. A loose, semi-structured interview 
guide (See Appendix 1), with suitable prompts, was prepared that encourages 
participants to be expansive in their accounts, if required.  However, the aim was to 
remain as flexible and non-directive as possible.   
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Sampling and recruitment: In qualitative research, the depth of the data is more 
important than the numbers in addressing the research questions (Frambach et al. 2013). 
A small number of information rich, in-depth interviews can have the same impact as 
many more, shorter interviews. Different sample sizes, depending on the qualitative 
approach, are cited from at least six for phenomenological studies, as with our study (i.e. 
a study of subjective experience), to approximately thirty-five for grounded theory 
research (Guest et al., 2006). A sample size of between five and twenty-five for 
phenomenological studies appears quite consistent within the literature (Creswell, 1998).  
As this study adopts an inductive approach, we do not seek generalisability based on 
large sample sizes, but rather the appropriateness and adequacy of the sample to yield 
a meaningful balance between thick data, and rich data (Tracy, 2010). Using these criteria, 
we decided to conduct individual interviews with ten ophthalmic surgeons (See Table 
5.1). Purposive sampling was used whereby surgeons who were known to have 
experience of performing only-eye surgery were invited to participate. Research that is 
field oriented and not concerned with statistical generalizability often uses non-
probabilistic samples. The most commonly used samples, particularly in applied research, 
are purposive (Miles & Huberman 1994). Purposive samples can be of different varieties, 
but the common element is that participants are selected according to pre-determined 
criteria relevant to a particular research objective.  
An eye was considered an ‘only eye’ when significant loss of vision in this eye 
would be deemed life-changing with profound impact on the quality of life by both 
patient and surgeon. The vision in the fellow eye (usually the RNIB definition of severe 
sight impairment <3/60 or worse +/- end-stage visual field loss) was considered as 
insufficient to maintain the patient’s current independent life-style and visual quality of 
life. 
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Table 5.1: Participant characteristics 
 
Data collection: The study was approved by the London – Chelsea Research Ethics 
Committee (Ref: 17/LO/1664) and conformed to the tenants of the Declaration of 
Helsinki; See Appendix 2. Consent from all participants was obtained prior to interview. 
Semi-structured face-to-face interviews were conducted by a university-based researcher 
(LJ). Two of the interviews were performed face-to-face via Skype. As per the guidelines 
by the World Health Organisation, an interview topic guide (See Appendix 1) was devised 
prior to commencing the study (Kajornboon, 2005). Details of the topic guide 
development are shown in Figure 5.1. Data collection took place between November 
2017 and April 2018. Median (Interquartile range) interview duration was 35 (31-40) 
minutes. Completed, signed consent forms were kept securely as part of the Research 
Master File. Each participant was assigned an identifying number, which was used for all 
other research records in this study. A separate password protected file was kept on the 
Principal Investigator’s computer detailing participants' names and their identifying 
numbers. This was the only link between participants' names and their identifying 
numbers. Field notes, recordings of interviews and interview transcripts were accessible 
ID Sex Years performing only-eye 
surgery 
Specialty 
 
UK/Non UK based 
P1 Male >20 G; AS UK 
P2 Male >10 G; AS Non-UK 
P3 Male >10 G; AS Non-UK 
P4 Male >10 G; AS UK 
P5 Male >20 G; AS Non-UK 
P6 Male <10 G; AS UK 
P7 Female <10 G; AS UK 
P8 Female >10 G; AS UK 
P9 Female >10 G; AS Non-UK 
P10 Male >10 G; P UK 
Key. G = glaucoma, AS = anterior segment, P = paediatric 
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only to the research team using password protected computer systems. All equipment 
used for recording and paper filed notes were kept securely as part of the Research 
Master File. Once final dissemination is complete, all research data will be stored for 5 
years as per University Hospital Birmingham NHS Trust guidelines. 
 
 
 
 
Figure 5.1: Process of interview topic guide formation. *Advisory group consisted of only-eye patients, 
consultant ophthalmologists, ophthalmologists-in-training, a psychologist and an ophthalmic research 
nurse, and established researchers in the field of ophthalmology. **Scoping exercise consisted of a 
preliminary pilot interview where suitability of interview questions was assessed. 
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Data management and analysis: The study was designed and reported following the 
guidance of the Consolidated Criteria for Reporting Qualitative Research (COREQ) for 
interview-based studies. All audio recorded interviews were transcribed verbatim via an 
online transcription service (www.sterlingtranscription.co.uk).  All interviews were coded 
using both manual and computer-based methods (NVivo 11; Nvivo data analysis 
software). A thematic analysis approach was employed when analysing the data; this 
approach pays attention to common themes inductively identified and described across 
all of the participant narratives (Braun & Clarke, 2006). The focus is on identifying extracts 
in the interview transcripts that appear relevant in the terms of the research questions, 
which can be collected into categories across the data set.  This is followed by the analysis 
at the broader level of themes, clustering different categories into potential overarching 
themes (Braun & Clarke, 2006). Two members of the research team (LJ and DT) 
independently interpreted all of the transcripts and developed preliminary codes based 
on impressions of recurring themes. Inter-rater reliability between the two coders was 
assessed by analysing a portion of the coded interview data (16% of total transcribed 
word count) using the kappa coefficient (κ). We established that the level of inter-rater 
reliability was more than acceptable between the two coders, κ = 0.46. There is debate 
in the literature regarding the sufficiency of the kappa statistic, however scores between 
0.40 and 0.75 typically reflect fair to good agreement beyond chance. (Fleiss, 1981; Landis 
& Koch, 1977). Following individual data interpretation, the research team met to reflect 
on all of the interview data and discuss any differences of opinion regarding the coded 
themes. Once the research team were in agreement of the meaning of quotes and 
suitability of coding choices, a coding framework was created featuring all of the 
identified themes. Finally, collected codes were grouped based on the concepts of only-
eye surgery they addressed, resulting in the identification of several emerging themes. 
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5.3 Results 
Data were indexed according to the different areas of only-eye surgery that were 
discussed. As shown in figure 5.2, we identified four key emerging themes relating to (1) 
Material risk (2) Strategies for risk reduction (3) Training (4) Emotional impact. Direct 
quotes taken from the transcripts are italicised. These quotes were examples chosen to 
illustrate the key themes that emerged from the interviews. All included excerpts are 
annotated with a code given to the corresponding surgeon with a numeric to identify 
the order in which they were interviewed. 
 
Figure 5.2: Diagram showing the main themes and subthemes that emerged from the surgeon analysis, and 
how different categories relate to each other. 
 
 
(1) Material risk 
A number of participants described concerns regarding the discussion of material risk 
during the consent process in only-eye surgery. There was an agreement that a 
conversation about the potential risks between the patient and physician is important. 
However, there were variances between the participants over how extensive such 
discussions ought to be.  
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The issue is you have to communicate what the material risk is. If the material risk 
is blindness, you have to communicate it. We have to articulate total extinction of 
vision, and I think that’s absolutely right and very important. (P1) 
I don’t think it’s necessary to dwell on it too much, but there needs to be a mutual 
understanding. I think it’s kinder in a way to not solely talk about that point, it 
needs to be tempered with a sense of realism.  (P7) 
It should be an open discussion, which it most of the time is.  There are patients 
who don't want to take part in that decision; they leave it entirely into your own 
hands.  That's fair; that's good enough. (P5) 
On occasion, the surgeons explained how they attempt to demonstrate the risks of only-
eye surgery to the patient. To do this, some used methods to exemplify what the patient’s 
life would be like if the surgery was not successful and the patient loses their vision. In 
addition, the surgeons supported the idea of family members being present when 
consenting only-eye surgery, to assist when deciding whether or not to go ahead with 
the procedure. 
When we consent a patient for only-eye surgery, we insist they bring their relative, 
their nearest and dearest, and maybe their kids as well, and we patch them up for 
three hours in clinic and we sit them outside so they are totally blind. So they’ve 
been totally blind for three hours when we consent them. I strongly suggest to the 
patient that they bring their loved ones to the consultation, whoever's looking after 
them, and involve them in the decision. Because these are the people, if things go 
wrong, they're going to be looking after the patient for the rest of their life. (P1) 
In other cases, the surgeons described how ensuring the patient is given a second or 
third opinion during the consent process, so that they are able to make an informed 
decision over whether to proceed with the surgery. 
When you’ve got patients that are high-risk only-eye, it’s always useful for the 
patient and surgeon if you’ve got two people doing the consent process. Certainly, 
joint clinics and multidisciplinary clinics allow for the opportunity for the patient 
to get a second or third opinion, so all are in agreement that they need this 
intervention. So, if something catastrophic does happen, and a patient goes blind, 
then at least they have that opinion from a number of people, not that it will be 
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any consolation, but at least the patient knows that a number of surgeons said the 
same thing, and I think that always helps. (P4) 
(2) Strategies for risk reduction 
Participants gave details about strategies they specifically integrate in only-eye surgery 
to help optimise outcomes. These were typically clinical in nature, such as ensuring 
optimal surgical instruments were available for the procedure, and that the most skilful 
clinic staff were assisting.  
I don’t want new nurses or scrub nurses or anybody else in my theatre at that time 
if it’s an only-eye. (P9) 
There was a general consensus there is often an aversion to delegating only-eye patients 
to clinic staff that are not of a suitable level of seniority.  
The head of the department or the Medical Director would do all the only-eyes 
himself, just to take responsibility for it. (P3) 
Participants identified behavioural techniques they adopt to prepare for only-eye 
surgery. Some participants adopted physical techniques such as motor imagery, whereby 
the surgical tasks are visualised and mentally performed prior to surgery, acting as a 
kinaesthetic opportunity to prepare for the procedure. Conversely, other surgeons relied 
on their faith and engaged in spiritual activity in order to help cope with the stresses of 
only-eye surgery. 
I do mental preparation. I will visualise the steps that I will go through. I will 
visualise what may go wrong, and what I will do to undo that. I visualise even the 
routine, the basic steps. (P8) 
With more complex cases, you go through in your mind the steps you are going to 
do. I’ve heard that Olympic divers do a very similar sort of thing. Before they even 
get up onto the podium they are going through their mind the exact number of 
turns and twists and whatever they have to do because it is over so quickly. It’s got 
to be all pre-programmed in their head. (P2) 
I’ve had some patients say to me, when I’ve asked them to sign a consent form for 
an only-eye operation, they say, well, we trust you, we have our faith in you, but 
we also have faith in God, okay, and we believe that God will get us through this. 
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In the same way, I have my faith as well. So, before I operate, I always pray. I take 
on some very difficult and crazy cases where sometimes I’ll be doing a lot of this 
surgery for the first time in my life, but I do it because I also have faith, and I pray, 
and I believe God helps me. (P4) 
One suggestion for reducing risk intra-operatively was to ensure only eye patients were 
operated on by teams of highly experienced surgeons, rather than a single surgeon. 
There’s been instances where another surgeon being there has made a 
crucial difference to the outcome, because they’ve spotted things that I may 
not have spotted because I was busy with something else. (P4) 
Yet, the consensus was that only eye patients are often operated on by just one surgeon. 
It’s a good idea to do difficult cases together, but because our outcomes are 
usually not lethal, it’s not about life or death, we can’t finance a second 
surgeon. (P3) 
In many branches of surgery, high-risk cases where the impact of failure is 
massive, are done by two surgeons, or teams of surgeons. In ophthalmology 
often there’s just one surgeon. I wonder if we are missing something just 
because it’s a small organ. (P1) 
Participants also expressed preference for avoiding this approach, and warned of 
potential hazards of high-stakes procedures being performed by teams. 
 
(3) Training 
The participants correlated a lack of surgical experience for ophthalmologists-in-training 
with concerns about the future provision of care for only-eye patients. For example, 
senior surgeons expressed doubt that the current training programme in ophthalmology 
would provide sufficient exposure to high-stakes procedures, such as only-eye patients. 
An explanation for the dearth in experience was the increased time restrictions on 
surgical activity for ophthalmologists-in-training. 
The trainees are not getting the training. The number of cases are dropping, they 
are shortening the number of training years, so you [trainees] are actually being 
compressed in both ways. (P8) 
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Participants reported their concerns that insufficient training and exposure to only-eye 
patients will ultimately impact on new ophthalmic surgeons’ ability to manage these 
cases upon reaching consultancy level. 
I would say, looking at the last five years, I can’t think of a single trainee who I 
would feel had the necessary technical ability, bravery, and surgical resilience to be 
safely allowed to do these cases. I just wonder what’s going to happen when they 
become young consultants. I just don’t think they will have the necessary skill set. 
(P1) 
They will become a consultant with probably less than 50% [experience] as the 
previous generation, so that will be a problem. (P8) 
One of the things that generally is consultant only is only-eye [surgery]. I think we 
try to protect our trainees as much as possible. But there has to be a tipping point 
where they’re going to have to deal with it at some stage. (P2) 
What you do not want is get to the end of your training, become a consultant, and 
then all of a sudden be tasked to operate on one of those [only-eye] cases. (P7) 
Participants acknowledged that more needs to be done in order to prepare 
ophthalmologists-in-training for operating on only-eye patients. There were 
recommendations on how to overcome the issue of insufficient experience, such as the 
advent of specialised training programmes for only-eye care, allowing for exposure to 
these patients whilst under close supervision. 
I think it’s important that we identify the best people, and then they are given 
focused training, focused mentoring by senior surgeons who do that kind of 
surgery, and gradually get them to that level. I think that’s what we need. In this 
kind of surgery, you’ve got to get the people who are the best, because patients 
only have one chance. This is what we call one-shot surgery. If we get it wrong, the 
patient’s blind for the rest of their life. (P4) 
(4) Emotional impact 
Participants in this study recognised only-eye surgery as high-stakes surgery, carrying 
potential for devastating adverse events. Amongst our cohort, a number of surgeons had 
experienced losing an only-eye, resulting in catastrophic loss of vision for the patient. 
Often in these cases, the surgeons described being burdened with a sense of personal 
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responsibility for their patient, and expressed how they are then required to shoulder the 
blame for losing the eye for the patient. These participants provided insight into the 
strong negative reactions they experienced following such incidents. 
We lost a true only-eye, he went blind. Well it doesn’t leave you, I still feel like I 
could have done something different. I feel like if the time was slightly different, if 
we weren’t so stressed, if we weren’t so under pressure, I think we would have said 
there’s something not quite right. I still feel partly responsible for him. (P8) 
For participants who had not yet experienced losing an only-eye, they expressed concern 
over how this would impact on their career and the psychological sequelae of such an 
event. 
I’m lucky not to have had an only-eye disaster, yet. I’ll probably remember that for 
the rest of my life, when that happens, which it probably will. (P10) 
The participants advocated the need for formal mechanisms to support surgeons after 
losing an only-eye, to help develop strategies to cope with negative surgical outcomes. 
I think there needs to be a better support mechanism. I think, if someone has lost 
an only-eye and they’re very distraught by it, they need a mentor to talk to, 
someone who has lost an only-eye. So, you need – a bit like the self-help groups, 
where you have psychological therapy. (P4) 
Yet, the participants noted that there are a lack of formal pathways to find professional 
support services in the event of losing an only-eye. Participants also noted perceived 
barriers when it came to seeking out such services. 
There’s no guidance on how surgeons can seek out help for themselves when 
incidents like this happen. (P8) 
I think we’re very busy. We don’t have time to do that [seek support services]. 
Something else would have to give. (P6) 
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5.4 Discussion 
Only-eye surgery can be challenging for the ophthalmic care team. In medicine, stories 
of healthcare experiences can provide a rich source of information to help generate new 
insights. However, qualitative research is frequently under-represented in ophthalmology 
(Jones & Jefferis, 2017), and yet has the potential to offer significant contributions to 
knowledge and understanding of eye care. We sought to explore ophthalmic surgeons’ 
experiences of performing high-stakes procedures on patients with only one seeing-eye. 
Discussion of risk is of paramount importance in only-eye surgery. Our findings 
highlight differences in how surgeons disclose material risks in only eye surgery. 
Participants stressed importance of patients’ understanding of risks of surgery, regardless 
of how unlikely adverse outcomes may be. Yet, other participants voiced concerns over 
a heavy focus on risks of vision loss, as surgery is generally successful. This discordance 
is pertinent given the landmark change in the position of the Supreme Court regarding 
informed consent (Edozien, 2015). Until recently, the UK Supreme Court followed the 
principles of the Bolam Test. Such principles state that, in the event of surgical 
complications, a surgeon would not be deemed negligent if they had acted the same 
way other competent surgeons would have (Newman, 2016). However, this paternalistic 
approach to medicine is no longer tolerated, as demonstrated by the introduction of the 
Modified Montgomery Test (Sokol, 2015). This standard of care obliges surgeons to 
provide sufficient information to patients, including disclosure of risks of proposed 
treatment.  In medicine, there is concern over the use of a ‘one-size-fits-all’ approach 
applied to heterogeneous populations (NCEPOD, 2010). For example, greater material 
risk should be attached to surgery on an only eye, as opposed to the same surgery on a 
patient with good bilateral vision. Yet, participants expressed aversion to appearing 
pessimistic when discussing surgical risks, a belief in contrast to the principles of the 
Modified Montgomery Test. Methods of demonstrating risks of only eye surgery included 
occlusion of the only eye. Our results indicate variances between surgeons regarding 
discussion of material risks in only eye surgery, suggesting the principles of the Modified 
Montgomery Test are yet to be fully recognised in this area of ophthalmology. 
Our study has interesting findings regarding how only-eye surgery is approached by 
ophthalmic surgeons. Indeed, a career in surgery not only requires extensive medical 
knowledge, critical thinking skills, and sharp motor control, but also endurance and 
stamina, both physical and psychological. Surgeons must be able to maintain attention, 
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make split-second decisions, and retain fine motor control throughout the entirety of a 
surgical procedure, sometimes lasting several hours. The complexities, implications, and 
risks associated with operations create a generally stressful environment (Arora et al., 
2010; Maher et al., 2013). Furthermore, advances in surgery continue to increase the 
demands on surgeons. It was acknowledged that only-eye procedures can evoke 
elevated levels of stress for the surgical team. Indeed, self-reported anxiety is higher 
when the procedure is considered high-stakes (Anton et al., 2015).  
There is a need to develop methods to reduce stress in the operating room, and also 
to maximise skill acquisition and retention in learning or simulated environments. Mental 
skills are psychological strategies used to help performers reliably achieve their ideal 
mental state for performance (Williams, 2010), and may be able to help surgical trainees, 
and even experienced senior surgeons, to reduce stress and enhance their learned skills 
in the operating room. Examples of mental skills exercises might include mental imagery; 
goal setting; energy management, i.e. relaxation strategies; and attention management. 
Mental skills training curricula have been shown to be effective at enhancing the 
performance of several groups who have to perform under high stress conditions such 
as military pilots during training exercises (McCrory et al., 2012), The United States Navy, 
Sea, Air, and Land teams during underwater demolition training (Selder et al., 1989), and 
amongst police special forces (Le Scanff & Taugis, 2002). In particular, over the past two 
decades, a variety of intervention techniques have been prompted to help athletes 
develop mental skills to enhance their performance in such sports as tennis (Daw & 
Burton, 1994) and swimming (Sheard & Golby, 2006). The success of such interventions 
has seen an increase in mental skills preparations being implemented amongst elite 
athletes in sports including rugby (Rowley et al., 2012), cricket (Jooste et al., 2013), and 
skiing (von Guenthner et al., 2010). This overlap between sport psychology and surgery 
is perhaps not surprising, as both require an element of goal setting and strong 
motivational benefits. However, many sports follow a ‘zero-sum’ game structure, 
whereby the total number of wins and losses adds up to zero, and thus one party benefits 
at the direct expense of another party (i.e tennis, chess, etc.). In contrast, the process of 
a surgical intervention can be much more likened to a ‘positive-sum’ game, where the 
strategic approach attempts to satisfy the desires and needs of all concerned (i.e. the 
patient, the surgeon, the patient’s family). For this reason, the stress applied to the 
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surgeon responsible for securing a successful result will inherently be larger, as in the 
event of an unsuccessful outcome, the losing party will far outweigh the winning party. 
Participants in this study reported a number of mental skills used to help optimise 
performance in these stressful procedures, including motor imagery. The use of mental 
skills and mindfulness have previously been shown to potentially reduce stress and 
improve performance (Stefanidis et al., 2017; Fernando et al., 2014). Moreover, evidence 
indicates that surgeons who undertake mental skills training have better outcomes on 
measures of anxiety (Stefanidis et al., 2017). Our results identify coping strategies used 
by surgeons before only eye surgery to optimise performance during stressful situations.  
Our findings introduced the concept of only eye surgery being performed by two or 
more surgeons. This intra-operative strategy for risk reduction was described as an 
opportunity for another expert to critique the procedure, in an attempt to ensure nothing 
is missed. However, some participants perceived this approach to be counter-productive, 
suggesting team procedures can lead to adoption of more risk-averse or overly foolhardy 
behaviours. The advocacy for only eye procedures performed by two or more surgeons 
echoes how exceptional cases are managed in other fields of medicine, such as 
cardiothoracic surgery. In this specialty, implementation of a Star Chamber, whereby 
surgeons refer complex or high-stakes patients to the Star Chamber who assess what the 
patient should be offered, has been used in an attempt to improve surgical outcomes 
(Nashef, 2017). If the Star Chamber recommend surgery, it is a requirement that the 
procedure is performed by a minimum of two consultants. Other disciplines in the UK 
are considering implementation of a Star Chamber (ACGBI, 2016), however there appears 
to be no such movement in ophthalmology. Yet, such initiatives as the Star Chamber may 
help to minimise intra-operative risks during only eye surgery.  
Participants described how medical training in the UK has experienced dramatic 
reform, and expressed concerns over how this may affect standards of care in 
ophthalmology. Changes in educational theory (Reznick & MacRae, 2006), and the 
European Working Time Directive (Department of Health, 2009) have limited training 
opportunities for ophthalmologists-in-training. As a result, procedures such as 
trabeculectomy feature less often in trainees’ timetabled clinical activity (Rodrigues et al., 
2013). Work-hour restrictions and a demise of the ‘mentor’ model in medical training 
may have damaging consequences for acquisition of technical skills and surgical 
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resilience (Cope et al., 2017). Indeed, consultant surgeons have reported concerns over 
capabilities of the newer generation of trainees and how this may impact patient care 
(Rashid et al., 2012). Although progress in technology has led to the advent of valuable 
training opportunities, such as ‘wet-lab’ simulations (Lee et al., 2006), such environments 
are unable to mimic the true reality of operating on a patient’s only eye. Participants 
stressed the essentiality of combatting these training barriers, and gave suggestions for 
purpose-designed training programmes for complex procedures. Such programmes may 
enable appropriate access to high-stakes patients and nurture the learning processes for 
ophthalmologists-in-training. This finding spotlights concerns with surgical training in 
ophthalmology, a problem first identified almost two decades ago (Gibson et al., 2002). 
If this trend continues, there may be necessity for specific training fellowships to gain 
clinical competency, and we propose that only eye training must not be overlooked. 
Another emerging theme was the importance of mentoring in only eye surgery. 
Participants described how a good mentor has helped them to become an effective only 
eye surgeon. Typically, a mentor will be a senior member in the field who guides a trainee 
professionally and personally by facilitating learning through observation and modelling 
(Cope et al., 2017). There is concern that mentoring has become a lost art in medicine 
(Rohrich, 2003), and participants in our study explained that a mentor can offer significant 
support when caring for only eye patients, and formal recognition of mentoring may be 
needed. In line with previous research, our results highlight barriers to mentorship as a 
lack of formal recognition of the role, resulting in time commitment issues and a scarcity 
of appropriate mentors (Entezami et al., 2012). Fostering of strong relationships between 
mentor and trainee could play a crucial role in alleviating concerns raised in this study 
about training in ophthalmology and only eye surgery. 
A number of participants in our study had experience of losing an only-eye, resulting 
in total extinction of vision for the patient, and usually a life of full-time dependency on 
others. Participants described their responses to these incidents and how the 
psychological sequelae has impacted their career as a result. A recurring sense of 
personal responsibility and blame was reported, and participants frequently remarked on 
the lack of formal and professional support for physicians when unpredicted outcomes 
occur. In medicine, the term ‘Second Victim’ was coined to recognise that, in addition to 
the crucial needs of the patient and their families when such events occur, the surgical 
team may also suffer in these devastating instances (Wu, 2000). Participants reported a 
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sense of fear at the thought of unfavourable results in only-eye surgery, and described 
their concern over a perceived lack of avenues to seek professional support in the event 
of such incidents. This finding is particularly noteworthy as the Royal College of 
Physicians has recently outlined ten areas for urgent action to obviate a crisis regarding 
the mental health of surgeons in the UK (Royal College of Physicians, 2015). Research 
estimates that almost 90% of physicians perceive a lack of available time to access 
support services when coping with Second Victim experiences (Hu et al., 2012). Growing 
attention is now being placed on the mental wellbeing of surgeons in the UK (Gerada, 
2017), and the importance of such support services as the Practitioner Health Programme 
is being realised (Brooks et al., 2011). However, it remains that only 57% of NHS trusts 
have a policy to support staff mental health (Sloan et al., 2014). Participants in our study 
perceived a lack of options for support for surgical staff in the event of poor outcomes 
in only-eye surgery, reflecting the dearth in recognition and understanding of the Second 
Victim phenomenon in the field of ophthalmology. 
The strengths of this study are that it is the first of its kind in ophthalmic surgery. By 
adopting a qualitative approach to this subject, a number of important themes have 
emerged which have provided an excellent basis for further work. The study is limited in 
that a small number of surgeons were interviewed and the surgeons in question were all 
experienced glaucoma surgeons. This may however be due to the nature of glaucoma in 
that there may be a greater proportion of patients who are only-eyed particularly in 
complex glaucoma practices. Furthermore it is important the future studies consider the 
views of less experienced surgeons. 
The implications of losing an only-eye are massive for both the patient and surgeon. 
This study clearly identifies important themes that are of great relevance to surgeons 
who regularly perform only-eye surgery. These include risk management, training, and 
emotional factors. Further work in needed in each of these areas to clearly define best 
practice to enable a safe and seamless patient journey. 
 
 
 
  
105 
 
5.5 Introduction – Patient experience 
It is often stressed that a diagnosis of glaucoma does not necessarily mean the patient 
will ultimately experience a total extinction of vision (Green et al., 2002; Crabb, 2016). 
Rather, estimates suggest that around 1 in 20 treated patients are at risk of serious visual 
impairment due to glaucoma (Saunders et al., 2014). Whilst these figures are likely to be 
somewhat comforting for the majority of those diagnosed with the disease, it remains 
true that a small number of patients will experience significant visual disability as a result 
of their glaucomatous vision loss. Furthermore, glaucoma has a progressive impact on 
patients’ daily activities and quality of life, whereby more advanced disease incurs more 
pronounced difficulties (Ramulu, 2009; Peters et al., 2015; Jones et al., 2017 [See chapter 
two]). As such, patients living with advanced-stage glaucoma will likely face exceptional 
challenges in their day-to-day lives compared to individuals with healthy vision, and even 
those living with mild or moderate glaucoma. 
In addition to the threat of visual disability, patients may need to undergo surgery 
to treat their glaucoma. When glaucoma cannot be controlled medically, surgical 
intervention may be required. Trabeculectomy is the most commonly performed surgical 
intervention in glaucoma and is generally successful at reducing IOP (Gedde et al., 2012), 
even in complex, high-risk populations (Shah et al., 2012). Advancements in education 
and technology have reduced the likelihood of complications after surgery (Kirwan et al., 
2013). However, the procedure remains associated with potential risks such as hypotony, 
or in more extreme cases, endophthalmitis (Edmunds et al., 2002). Furthermore, the 
longevity of trabeculectomy is difficult to predict (Landers et al., 2012) and factors such 
as race and age can affect surgery success rates (Broadway & Chang, 2001). 
  Researchers have recognised the unique impact ophthalmic surgery can have on 
patients’ psychological wellbeing (Nijkamp et al., 2004; Marback et al., 2007). However, 
there has been limited investigation into the experiences of ‘only-eye’ patients 
undergoing ocular surgery. In this instance, ‘only-eye’ refers to an eye where significant 
loss of vision would have a profound impact on patients’ quality of life and would likely 
result in meet the criteria for severe sight impairment. Glaucoma only-eye surgical 
patients are those who require surgical intervention on the better-seeing eye in an 
attempt to slow glaucoma progression. The glaucoma only-eye population are among 
those who are at risk of significant visual impairment, are likely to be living with severe 
visual disability, and face the daunting reality of undergoing surgery on their only-eye. 
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As such, research into the experiences of this cohort of advanced-glaucoma patients is 
warranted. The aim of this study is to learn more about the realities of only-eye surgery 
from the patients’ perspective, before, during, and after surgery. In particular, we were 
interested in learning how patients cope when undergoing these high-stakes surgeries 
and what can be done to improve the surgical journey for only-eye patients.  
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5.6 Methods 
Individuals who met our criteria for only-eye patient were invited to participate in an 
interview. As discussed in Section 5.2, an eye was considered an ‘only eye’ when 
significant loss of vision in this eye would be deemed life-changing with profound impact 
on the quality of life. The vision in the fellow eye (usually <3/60 or worse +/- end-stage 
visual field loss) was considered as insufficient to maintain the patient’s current 
independent life-style and visual quality of life. 
Participants were required to have undergone glaucoma surgical intervention on 
their only-eye. There was no specification for amount of time since operation. 
Furthermore, participants were required to have the ability to communicate in English 
and provide informed consent. Details of patient characteristics and surgical history are 
shown in Table 5.2. The study was approved by the London – Chelsea Research Ethics 
Committee (Ref: 17/LO/1664) and conformed to the tenants of the Declaration of 
Helsinki; See Appendix 2. Consent from all participants was obtained prior to interview. 
Participant information was anonymised before being entered into a secure computer 
database. 
Semi-structured interviews were conducted between December 2017 and April 
2018. Interviews were audio-recorded with the permission from the participant. As 
discussed earlier in this chapter (See section 5.2), an interview topic guide was created 
prior to data collection. Interview questions were open ended and asked in such a way 
that required minimal interviewer input and encouraged detailed responses from 
participants. Care was taken not to ask leading questions, although prompts were 
occasionally used to encourage participants to expand on their responses. It was 
emphasised prior to the interview that there were no right or wrong answers and that 
participants would be given the opportunity to expand or clarify any points at the end of 
the interview. 
Interviews were conducted face-to-face by a male university-based health 
psychology researcher (LJ). The majority of interviews were conducted with only the 
participant and researcher present, but a small number of participants chose to have a 
friend or family member present in the room. The study followed the COREQ. Audio files 
were transcribed and analysed. As per the data analysis described in section 5.2, a 
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thematic analysis approach was adopted. Similarly, transcripts were read and re-read, 
themes were identified, and example quotes were chosen to illustrate these themes 
 
 
Table 5.2: Participant characteristics 
  
Code Age Sex Ethnicity Diagnosis Most recent only-eye 
procedure 
G1 66 Male Caucasian  POAG Phacoemulsification  
G2 58 Female Caucasian SOAG Baerveldt Tube 
G3 54 Female Caucasian PCG Trabeculectomy 
G4 59 Male Caucasian JOAG Trabeculectomy 
G5 66 Male Afro Caribbean  POAG/SACG Trabeculectomy 
G6 61 Male Caucasian JOAG Trabeculectomy 
G7 74 Male Indian Asian POAG Phacoemulsification 
G8 73 Female Caucasian POAG Trabeculectomy 
G9 32 Female Bangladeshi JOAG Trabeculectomy 
G10 29 Male Indian Asian SACG Trabeculectomy 
G11 49 Male Caucasian SACG Baerveldt Tube 
Key. POAG = primary open angle glaucoma, SOAG = secondary open angle glaucoma, 
PCG = primary congenital glaucoma, JOAG = juvenile open angle glaucoma, SACG = 
secondary angle closure glaucoma 
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5.7 Results 
Data were indexed according to the different areas of only-eye surgery that were 
discussed. Figure 5.3 shows the three key themes that were identified; (1) emotional 
impact of only-eye surgery; (2) coping with only-eye surgery; (3) improving the patient 
surgical journey. Direct quotes taken from the transcripts are italicised. These quotes 
were examples chosen to illustrate the key themes that emerged from the interviews. All 
included quotes are annotated with a code given to the corresponding participant. 
 
Figure 5.3: Diagram showing the main themes and subthemes that emerged from the patient analysis, and 
how different categories relate to each other. 
 
(1) Emotional impact of only-eye surgery 
Participants described their strong negative emotional response to learning they must 
undergo surgery on their only-seeing eye. A common theme across the patient narratives 
was an overwhelming sense of fear: 
I walked out of there and I was absolutely devastated, completely and 
utterly devastated. The whole world came crushing down around my 
shoulders, I went downhill very, very quickly. If you looked at it today you'd 
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probably say I was majorly depressed, I didn't know how to get out of it. 
(G2) 
Along with the initial distress of learning of the necessity of only-eye surgery, a number 
of participants reported a sense of fear regarding the potential outcomes of surgery: 
Nothing in life is guaranteed and you do put your life in the surgeon’s hands 
really.  When I met my surgeon it was - I've got to be honest, I was terrified 
because I just had no idea where I was going and what was going to happen. 
(G6) 
I think more than anything it's the worry that if something goes wrong 
you've got nothing. (G4) 
When you're at the first stages it's very scary because you don't know what's 
going on. (G11) 
The fear of potentially negative outcomes of surgery was particularly pronounced in 
patients who had a responsibility for others, where they had concerns as to how they 
would be able to continue in their care giving role: 
It was a horrendous time, absolutely horrendous time. My experiences of 
going into an operation with a one and only eye, one word to describe it is 
absolutely petrifying. You don't know what's going to happen. That was 
very daunting because I'd got a very young little girl, and didn't know what 
was going to happen when I came out of it. (G2) 
In some cases, participants had witnessed a family member losing their vision to 
glaucoma, and this close involvement made them particularly fearful for themselves: 
My brother has got the same condition but he's gone blind, so that was a 
worrying factor for myself. (G3) 
Indeed, the thought of undergoing only-eye surgery was worrisome for many 
participants. Yet, a number of participants reported that the most concerning aspect of 
their surgical journey was the post-operative period, where there was significant anxiety 
immediately after surgery about the surgical outcomes:  
I think the scariest bit was when you come out of surgery, where you come 
out of the theatre and you've got an eyepatch and it's scary. It was scary and 
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you think what am I going to see when I get this taken off - will I be able to 
see when they take the eye patch off. (G8) 
Sometimes I wake up crying. I just feel very scared during the night [after 
surgery] and I don't have anyone to say to that I'm scared. (G9) 
When I had my second surgery when I first woke up I couldn't see 
straightaway and I panicked like Hell. Although your surgeon has told you 
that everything has gone fine, everything is well, you're still lying there 
thinking, okay, I'll find out tomorrow morning when these bandages come 
off. I think that's where I've probably felt the most isolated, over that night. 
(G2) 
Immediately after the operation and during that first night, you don't know, 
and the next morning they take off the eye patch and that was a relief 
because on all occasions I could still see.  But between the operation and 
taking that eye patch off, pure panic. (G8) 
I lay in bed for six weeks, I couldn't see the light above me and if I'd had a 
gun I'd have put a bullet in my head. I used to sit up and break my heart. 
(G11) 
Many of the participants in this study had undergone a substantial number of surgical 
interventions. A common consensus was that ‘failed’ surgery, i.e. where IOP was no longer 
stabilised, was a particularly emotional event. One participant described their feeling of 
desperation and the hope that more could be done to save their vision: 
It started to reject. I panicked, really, really panicked. It was a tough time, it 
really really was. My surgeon said to me - I can't promise you anything but 
we'll give anything a go. At that point I was like just try anything; just do 
anything, anything you can do. (G2) 
The fear of being unable to cope with further visual loss was a common worry for 
participants, with concern being expressed as to how they would be able to continue life 
with very limited residual vision. This was a particularly concerning aspect: 
I'll be honest with you, I said to the wife, I said if I'd lost my sight you would 
have found me in the road [deceased].  Because I'm not the sort of person, 
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I just couldn't - I meet people who have been remarkable by coping with it.  
I quite frankly just don't think I could. (G6) 
(2) Coping with only-eye surgery 
There was an array of coping mechanisms described by the study participants regarding 
what helped them to understand and come to terms with only-eye surgery. Participants 
frequently expressed that building a good relationship with their care team facilitated a 
sense of trust which helped them to cope with the anxieties relating to surgery. The 
responses highlighted the importance that is placed on continuity of care in these high-
stakes surgeries: 
I feel safe with the physician, but that's only because the doctor, the 
surgeon, I've got a relationship with them.  I've got his number on my 
phone, he's been there for me but I think the journey leading up to that is 
the scariest part. (G11) 
My doctor, I say that he is a gift from God. He knows how to speak to the 
patient and that’s the main thing. (G7) 
I think a lot of it has got to do with the confidence that your surgical team 
give you. The more they discuss with you and what may happen, what your 
thoughts are about it, what they're going to attempt to do. To me, going in 
there knowing that it could go the wrong way as well as the fact that it could 
come out the right way is a very big thing. (G2) 
Other coping mechanisms came from family support in both emotional and practical 
ways. Emotional support from family and friends in negative times, as well as practical 
support, such as when instilling eye drops, were both considered by participants to be of 
vital importance to their wellbeing: 
I was extremely fortunate that I've got a very good family around me. It is 
devastating and you need the support of your family. (G2) 
Coping with only-eye surgery was often helped by developing positive personality traits, 
such as having an optimistic attitude towards surgery. Participants described how they 
would attempt to maintain a positive outlook in order to reduce their concerns about 
glaucoma: 
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To come out of surgery with anything at all is better than what the future 
held for me anyway. I think excited is another word, because you are excited 
at what's going to happen. (G2) 
I wasn't fearful because I was confident that whatever happened, I had made 
the right decision. (G1) 
 
 (3) Improving the patient’s surgical journey 
The participants in this study described the immense impact glaucoma has had on their 
lives and the difficult challenges they have faced, including significant loss of vision and 
multiple surgical procedures. Many of the participants explained the situations which 
they found to be particularly traumatic, and provided some suggestions as to what could 
be done to improve patients’ experiences of only-eye surgery. 
In some cases, participants described how their healthcare professional lacked empathy 
when delivering the diagnosis of glaucoma and discussing the management of the 
disease: 
It was a very cold, callous response and it was jolly insulting. As it got worse 
they said you're beyond what we can do here.  If we don't refer you to 
somewhere else you'll lose your sight forever. (G6) 
Some participants felt that their healthcare provider was notably bleak when discussing 
the progression of their glaucoma, describing how they were informed nothing could be 
done to protect them from this disease: 
The consultant sat there and he said I'm really sorry, there's nothing I can 
do for you sweetheart. He said that's what the glaucoma does to you. I 
remember my husband saying is there absolutely nothing that you can do. 
He said no I'm sorry. He said you're going to go blind and that's it. (G2) 
It was suggested that healthcare providers must do more in order to bridge the 
intellectual gap between themselves and their only-eye patients to ensure that treatment 
regiments are patient-centred and help them to understand their diagnosis: 
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Surgeons have somehow got to try and bridge the intellectual gap to 
become empathetic towards the patients as well, especially in one eye 
surgery. (G6) 
Moreover, participants described the importance of a more personal and humanised 
approach to only-eye surgery: 
Yeah so it's being made to feel you're a person, not a number on the list. 
(G8) 
There were also practical suggestions on how to make the only-eye surgical experience 
less daunting for the patient. Examples included music to help soothe the patient and 
relieve anxiety, as well as allowing relatives and caregivers to remain with patients while 
preparing to undergo surgery: 
I'm very nervous, really. I like to maybe have some entertainment, in my 
perception anyway. Like having a bit of nice music in the background. (G9) 
My husband was allowed to stay with me until I actually went - not into 
theatre, but just outside it. He came with me as they were taking me down 
there. I know that's not always possible because of things that happen. I 
think it's just people talking to you and telling you what's going to happen, 
isn't it? Making you feel safe and comfortable. (G2) 
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5.8 Discussion 
To our knowledge, this is the first study to investigate only-eye patients’ experiences of 
undergoing glaucoma surgery on their better-seeing eye. Surgery is a major trauma and 
is associated with significant patient anxiety (Munafò & Stevenson, 2001). In 
ophthalmology, patients have a tendency to show high levels of anxiety during the pre 
and postoperative periods, as well as during surgery (Marback et al., 2007). Reasons for 
ocular surgical anxiety are multifactorial, for example, anxiety may be the result of a lack 
of information about the procedure, expectations of results, and previous negative 
surgical experiences (Nijkamp et al., 2002; Nijkamp et al., 2004). Many of the participants 
in this study had undergone a number of glaucoma surgeries and reported aspects of 
visual disability as a consequence of their glaucoma. Indeed, participants reported 
feelings of fear and distress when told of the requirement of surgery on their only-eye. 
A number of participants expressed that their fear was at its most intense after surgery, 
whilst the eye was bandaged and occluded, thus not knowing the outcome of the 
procedure. This finding is in line with previous evidence that self-reported anxiety is high 
on the day after surgery for cataract patients due to concerns over what to expect from 
surgery (Nijkamp et al., 2002). This finding emphasises the high importance of 
postoperative counselling by patients’ healthcare teams to ensure the patient is given 
adequate information on how the surgery went. This is especially important for only-eye 
patients where negative surgical outcomes might incur significant visual disability. In 
addition, previous research highlights that self-reported postoperative anxiety is higher 
when the individual has already undergone a previous ocular surgery (Foggitt, 2001; 
Nijkamp et al., 2004). This factor is important to consider for only-eye surgery as, at least 
in this study, many only-eye patients are likely to have undergone previous ocular 
surgeries given their advanced disease state, and therefore it may be beneficial to 
introduce extra precautions to help reduce postoperative anxiety.  
Participants in this study described a number of coping mechanisms used to help 
manage their anxieties relating to only-eye surgery. Typically, participants described their 
reliance on supportive family members and friends, or developing positive personality 
traits to help cope with glaucoma surgery. Effective coping is an important component 
of good wellbeing and quality of life. Patients living with chronic illness who are able to 
cope with their disease are more likely to report improved subjective health, less distress, 
less fatigue, and more energy (Lorig et al., 1999; Lorig et al., 2003). Previous evidence has 
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found that glaucoma patients often adopt specific behaviours and techniques to help 
adapt to their glaucomatous vision loss (Glen & Crabb, 2015). Our findings shed light 
onto how glaucoma patients cope when undergoing high-stakes surgical procedures. 
Knowledge of coping strategies are important when understanding the surgical journey 
of glaucoma patients, and may ultimately help to provide better insight into the impact 
of glaucoma and help to inform patients, as well as professionals specialising in eye-care, 
about potential management strategies and coping behaviours relevant to glaucoma 
surgery. 
Participants advised that more needs to be done to improve the surgical journey 
for only-eye patients in the hospital eye service. There were a number of suggestions on 
how this could be done, such as greater support from the care team, reduced separation 
from family, and specific environmental changes. For many participants, a key factor was 
the need to feel supported by their surgeon and care team. Previous literature has shown 
that a supportive care team who are able to comfort patients and help them to 
understand their diagnosis is fundamental to fostering a trusting relationship between 
patient and surgeon (Cross et al., 2009). Our findings echoed these sentiments, where 
participants expressed feeling safe in their surgeon’s hands, and that they would be 
confident that the care team would be able to help if surgery did not go to plan. In the 
current climate this may be a particular challenge as surgical rotations can often be 
geographically diverse, where surgeons may be required to move from institution to 
institution, undermining the ability to build significant relationships and provide 
continuity of care to patients. Yet, as our findings demonstrate, continuity of care appears 
to play an important role for patient wellbeing. While many of the study sample reported 
a good relationship with their healthcare professionals, a number of participants reported 
negative experiences, such as a lack of empathy or a dogmatic attitude when discussing 
surgery. Participants described how these behaviours displayed by their care team led 
them to develop a fatalistic attitude, believing that nothing could be done to save their 
vision and that they would experience blindness as an ultimate result. Evidence indicates 
that such attitudes may result in patients delaying or avoiding surgery (Temporini et al., 
2002), which could result in further visual loss. As such, it is imperative for the surgical 
care team to be aware of the importance of the patient-surgeon relationship, including 
partnership, trust, and confidence, particularly when patients are at risk of significant 
disability as a result of delayed surgery.  
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 In addition to forging supportive patient-surgeon relationships, participants 
described some practical elements to only-eye surgery which may improve the surgical 
experience. The use of music at various stages in the surgical process was desired by 
some participants. Yet, evidence suggests that music may have no influence on patients’ 
surgical anxiety (Allen et al., 2001). It is advisable that this be discussed between the 
patient and their care team on an individual basis. Participants also reported that 
hospitalisation due to surgery results in separation from their supportive others, which 
further compounded their feelings of anxiety and distress. One solution was to allow 
extended visiting hours for only-eye patients and allowing supportive others to be 
present when preparing for surgery. 
 To conclude, surgical intervention on an only-eye is a significant event for 
patients living with glaucoma. Learning about the necessity of surgery, and concerns of 
the outcome post-operatively represent particularly worrisome periods for only-eye 
patients. However, a number of coping mechanisms may be employed to help manage 
the anxieties of only-eye surgery, and improvements in healthcare delivery for only-eye 
patients are available. The findings of this study may be used to help inform patients, 
their carers, and those working in the hospital eye services about the realities of only-eye 
surgery, the challenges to overcome, and potential strategies for effective coping and 
service delivery. 
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Chapter Six – Summary of main findings and future work 
6.1 Overview of findings 
The aim of this work was to investigate aspects of the patient journey in glaucoma using 
a reductionist approach, focusing on the early and late stages of the disease. The work 
supports the large body of literature evidencing the negative effect of glaucoma on 
patients’ quality of life. Specifically, this work emphasises that glaucoma can impair 
patients’ vision-related quality of life even in the early stage of the disease, as well as 
having a more profound effect later in the disease. Both quantitative and qualitative 
methods were used when addressing the research questions and add to the existing 
knowledge of the patient journey in glaucoma. This thesis identified and addressed 
prominent gaps in the literature surrounding the impact of glaucoma and these are 
summarised here: 
The study reported in Chapter 2 evaluated the relationship between vision-related 
quality of life and visual field loss in people from glaucoma clinics. Trends in responses 
on the NEI VFQ-25 were assessed against better-eye MD using a linear regression model 
and a spline-fitting method that can highlight where a monotonic relationship may have 
different stages. The analysis highlighted that on average a patient loses approximately 
2 units (out of 100) on the NEI VFQ-25 for every loss of 1 dB better-eye MD, up to 
approximately -5dB. Deterioration then appears to slow before a more rapid phase of 
change of around 4-5 units per 1dB loss after better-eye MD worsens beyond -15dB. The 
results of this study support the concept of a visual field threshold for severe functional 
impairment in glaucoma and challenges evidence which indicates a linear decline in 
vision-related quality of life and worsening MD. 
In Chapter 3, responses on general health and disease-specific PROMs were assessed 
for group differences between trial arms for patients in the UKGTS. The average 
percentage change on PROMs was similar for patients in both arms of the trial with no 
statistically significant differences between treatment and placebo groups (EQ-5D, p = 
0.98; EQ-5D VAS, p = 0.88; SF-36, p = 0.94, GQL-15, p = 0.66; GAL-9, p = 0.87). However, 
there were statistically significant differences between stable and progressing patients, 
as determined by visual fields, on glaucoma-specific PROMs (GQL-15, p = 0.02; GAL-9, p 
= 0.02) but not on general health PROMs (EQ-5D, p = 0.62; EQ-5D VAS, p = 0.23; SF-36, 
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p = 0.65). The findings suggest that PROMs, specifically those used in the UKGTS, may 
not be sensitive enough to detect clinical changes in glaucomatous disease. In addition, 
this study evidenced that the current instruments used to measure quality of life are 
unlikely to capture all consequences of glaucoma that are relevant to the patient. The 
results have implications for the design of future glaucoma clinical trials. 
The work described in Chapter 4 investigated the equivalence of measurement 
outcomes between patients attending a standard glaucoma care service, where patients 
see an ophthalmologist in a face-to-face setting, and a virtual glaucoma clinic. Average 
MD measurements for patients in the virtual clinic were compared against a ‘big data’ 
repository of patients attending a standard glaucoma care service, which was used to 
create expected limits. The total number of patients scoring outside the 90% expected 
limits was lower than what was allowed for, suggesting patients attending a virtual clinic 
have equivalent outcomes on the visual field test to patients in standard care. These 
results may help to lower the burden of hospital visits for patients with stable, early stage 
glaucoma. 
In Chapter 5, experiences of only-eye surgery were investigated. In the study described 
in this chapter, qualitative interviews were carried out among both patients who have 
undergone surgical intervention on their only-eye, as well as surgeons performing these 
types of procedures. Interview transcripts were thematically analysed and generated a 
number of key themes relevant to only-eye surgery. For the surgeons, key themes 
included material risk, strategies for risk reduction, training, and the emotional impact of 
surgical complications. For the patients, themes related to the emotional impact of 
undergoing only-eye surgery, coping mechanisms, and how to improve care systems. 
This study was the first to assess experiences of only-eye surgery using a qualitative 
methodology and the results should inform future patient and professionals about the 
realities of these high-stakes surgeries. 
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6.2 Future work 
The studies reported in this thesis go some way towards improving the understanding of 
the patient journey in glaucoma. Yet, these research outputs also raise a number of 
questions which have the potential to be addressed in future work. Specific ideas for 
future research relating to each individual chapter are discussed in the following section:  
Chapter 2 demonstrated that the rate of decline in glaucoma patients’ vision-related 
quality of life begins to slow after the MD in the better-eye is reduced to approximately 
-5dB. This slow decline remains apparent until better-eye MD is reduced to –dB or worse, 
whereby a rapid decline in vision-related quality of life occurs. However, we did not have 
data regarding the rate of visual field progression amongst the study participants, and 
this is likely to have an impact on vision-related quality of life. A future study whereby 
vision-related quality of life and better-eye MD are assessed longitudinally and evidence 
of a gradual then sudden decline are investigated would be an important addition to the 
literature. In addition, this analysis could be repeated using instruments other than the 
NEI VFQ-25, such as glaucoma-specific PROMs to look for evidence for decline in vision-
related quality of life as glaucoma worsens. 
Chapter 3 evidenced that group differences on PROM responses only emerge when 
comparing stable and progressing patients on instruments that are specific to glaucoma. 
Yet, PROM data were collected at only two time points, 24-months apart. Future research 
should be aimed at determining PROM sensitivity when measured at more frequent time 
points and over a longer duration. In addition, new methods of assessing patient-
reported quality of life are being realised, such as the use of computer adaptive testing. 
Compared to traditional PROMs, computer adaptive testing requires fewer items to arrive 
at equally precise scores reducing test burden, and potentially enhancing validity and 
reliability. Currently, several item banks and computer adaptive tests for glaucoma are 
being constructed, but none are available for wide use (Khadka et al., 2015; Matsuura et 
al., 2017). Once available, replicating the study described in this chapter using computer 
adaptive testing will make for important future research. 
Chapter 4 indicated that patients attending a virtual glaucoma clinic are likely to have 
similar measurement results on the visual field test as patients who are monitored in 
standard glaucoma clinics. Yet, the number of available measurements for the virtual 
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clinic patient cohort was quite small, where the average number of clinic appointments 
was three. At the time of conducting this study, the virtual glaucoma clinic was a relatively 
new addition at the hospital eye service where the data were collected. Future work 
should address questions regarding the equivalence of visual field outcomes over a 
longer duration of time. Furthermore, this study assessed only visual fields which is but 
one measurement of glaucoma status. Future work is needed to assess the equivalence 
between virtual and standard clinics on other measures of glaucoma disease.  
Chapter 5 investigated the patient and surgeon experiences of only-eye surgery. This 
was an exploratory study with the aim to increase the understanding and improve the 
patient experience of only-eye surgery. Future work should aim to gain more 
perspectives from patients and surgeons about only-eye surgery, possibly through the 
use of questionnaire or survey methodologies. Furthermore, the research group involved 
with the study described in chapter 5 have planned a further study into the perspectives 
of high-stakes ocular surgery. For this study, a research proposal has been drafted (by LJ) 
relating to surgeon experiences of performing paediatric glaucoma surgery. The purpose 
and background of this proposed study are described in brief below. 
Purpose and background of proposed investigation: Childhood glaucoma is a relatively 
uncommon, potentially blinding paediatric condition. The disease represents a significant 
public health concern due to the number of life-years potentially affected by the 
condition (Aponte et al., 2010). In the United Kingdom, the annual incidence of children 
being born with glaucoma is estimated to be approximately 1 in 18,500 births 
(Papadopoulos et al., 2007). Childhood glaucoma can have serious and significant 
implications on patients’ development, education, and quality of life (DeCarlo et al., 
2012). 
The primary treatment for paediatric glaucoma is surgery (Taylor et al., 1999), and this is 
often performed during childhood years. The most commonly performed paediatric 
glaucoma surgery is goniotomy, whereby incisions are made in layers of the eye’s tissue 
in an attempt to reduce intraocular pressure and slow the damage that is caused by 
glaucoma. The procedure requires careful surgical planning and patient positioning. The 
management of paediatric glaucoma can be challenging for the surgical care team. The 
success rate of surgery is variable, with success estimates ranging from 30-90%, 
depending on the age and ethnicity of the patient (Al-Hazmi et al., 2005; Chang et al., 
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2017), and repeat procedures are often required. Complications are rare, but pose as a 
significant threat to the patients’ remaining vision (Chang et al., 2017). 
 
Figure 6.1: The authors named on this proposal are closely involved with promoting ophthalmic care and 
public health. The images shown on the right come from the educational project led by this research team 
entitled ‘Prize your Eyes’ whereby children were asked to reflect on the causes and impact of major eye 
disease. 
 
Given the associated risks of surgery, coupled with the significant number of life-years at 
stake, a career as a paediatric glaucoma surgeon can be physically and psychologically 
demanding. Paediatric glaucoma surgeons will often have to shoulder the burden of 
negative surgical outcomes, as well as coping with reactions from family members, 
possible judgement from colleagues, and the possible threat of litigation or even 
disciplinary proceedings (Turner et al., 2016). It can be difficult to prepare 
ophthalmologists-in-training for the psychological sequelae of paediatric glaucoma 
surgery. Research indicates that self-reported intraoperative stress and anxiety is highest 
amongst surgeons when operating on complex or high-risk patients (Anton et al., 2015), 
and paediatric glaucoma surgery can often fit both these criteria. For that reason, we 
believe that research into how surgeons approach paediatric glaucoma surgery, such as 
the surgical logistics, and management of performance anxieties is warranted. 
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Appendix 1 Indicative interview topic guide (Chapter 5) 
 
Opening question: 
 
For patients: I am interested to hear about your experience of having 
surgery on your (right/left) eye.  Can you say a bit about how that came 
about?  
 
 
For surgeons: I am interested to hear about your experiences of performing 
only-eye surgery.  Can you say a bit about how these came about?   
 
 
Examples of prompts that may be used as required: 
 
Is there a time/moment/episode that stands out?   
 
Can you reflect back on any high points/low points? 
 
Is there anything in particular that changed how you saw things?  Or how 
you acted?   
Or felt? 
 
Can you think of something that happened, which seemed trivial at the time, 
but which became more significant later? 
 
Do you have a sense of any unfinished business about anything? 
 
If you could go back in time to the beginning of this story and replay events, 
how might it be different? 
 
Winding down: 
 
Your story/ies have given me a fascinating insight into things.  Do you think 
there is anything else I could have asked, or that you want to add? 
 
If anything occurs to you afterwards, here is my email.  I’d welcome further 
comments. 
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Appendix 2 Research Ethics Committee meeting attendance (attended by LJ), 
Research Ethics Committee, and Health Research Authority study approvals 
(Chapter 5) 
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